Document:

EX-4.17

 Exhibit 4.17 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such
excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
 Execution Version

 AMENDED AND RESTATED SHAREHOLDERS AGREEMENT 

THIS AMENDED AND RESTATED SHAREHOLDERS AGREEMENT (this “Agreement”) is made and entered into as of January 8, 2021 by and
among: 
  

	(1)	 VISEN Pharmaceuticals, a company established under the laws of Cayman Islands (the “Company”);

  

	(2)	 The Person(s) listed on Part I of Exhibit A hereto (each individually a “Series A
Investor” and collectively, the “Series A Investors”); 

  

	(3)	 The Person(s) listed on Part II of Exhibit A hereto (each individually a “Series B
Investor” and collectively, the “Series B Investors”; the Series A Investors and the Series B Investors, collectively, the “Investors”, and each individually, an “Investor”);

  

	(4)	 VISEN Pharmaceuticals HK Limited, a private company limited by shares and a wholly owned subsidiary of the
Company established under the laws of Hong Kong (the “HK Subsidiary”); 

  

	(5)	 VISEN Pharmaceuticals (Shanghai) Co., Ltd.
(维昇药业(上海)有限公司), a limited liability company and a wholly owned subsidiary of the HK Subsidiary incorporated under the laws of the People’s Republic of China
(excluding Hong Kong, Macao and Taiwan, the “PRC”) (the “WFOE”); and 

  

	(6)	 VISEN Pharmaceuticals (BVI) Limited, a private company limited by shares and a wholly owned subsidiary of the
Company established under the laws of the British Virgin Islands (the “BVI Subsidiary”). 

 The Company, the HK
Subsidiary, the WFOE and the BVI Subsidiary, together with all direct or indirect subsidiary of each (whether now in existence or formed in the future), are referred to collectively herein as the “Group Companies”, and each, a
“Group Company”. Each of the forgoing parties is referred to herein individually as a “Party” and collectively as the “Parties”. 

RECITALS 
 A. The Company,
the HK Subsidiary, the WFOE and certain Investors are parties to that certain Shareholders Agreement dated as of November 7, 2018 (the “Prior Agreement”). 

B. The Company and the Series B Investors have entered into a Share Purchase Agreement dated as of the date hereof (the “Share Purchase
Agreement”), under which, among other things, the Company shall issue and allot certain number of Series B preferred shares of the Company, par value US$0.0001 per share (the “Series B Preferred Shares”) to the Series B
Investors at the Closing. 
 C. The Share Purchase Agreement provides that the execution and delivery of this Agreement by the Parties shall
be a condition precedent to the consummation of the transactions contemplated under the Share Purchase Agreement. 

  
 1 

 D. The parties to the Prior Agreement now desire to amend and restate the Prior Agreement by
entering into this Agreement. 
 E. Unless otherwise defined in this Agreement, capitalized terms used in this Agreement shall have the
meanings set forth in the Share Purchase Agreement. 
 NOW, THEREFORE, in consideration of the foregoing recitals, the mutual promises
hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 

1. INFORMATION RIGHTS; BOARD REPRESENTATION. 

1.1 Information and Inspection Rights. 

(a) Information Rights. The Company covenants and agrees that, commencing on the date of this Agreement, the Company shall deliver to
each holder of Preferred Shares representing no less than [***] percent ([***]%) of the Company’s total issued and outstanding Ordinary Shares (calculated on a fully-diluted and as-converted basis) who is
not a Competitor (as defined below) (each such holder of Preferred Shares, a “Rights Holder”): 
 (i) within thirty
(30) days after the end of each fiscal quarter, unaudited quarterly consolidated financial statements and other documents reflecting the business activities and performance (including but not limited to tax filings and management reports) for
such quarter and analysis of the Group Companies’ business operation; 
 (ii) within forty-five (45) days after the end of each
fiscal year, unaudited annual consolidated financial statements for such fiscal year and implementation of the budget for such fiscal year; 

(iii) within four (4) months after the end of each fiscal year, audited annual consolidated financial statements for such fiscal year,
audited by the accounting firms reasonably acceptable to the holders of a majority of the issued and outstanding Series B Preferred Shares and Series A Preferred Shares (collectively, the “Preferred Shares”), voting together as a
single class and on an as-converted basis (the “Majority Preferred Shareholders”); 

(iv) prior to thirty (30) days before the end of each fiscal year, an annual budget and business plan for the next fiscal year; and 

(v) promptly upon the written request by any Rights Holder, such other information as such Rights Holder shall reasonably request from time to
time, including, without limitation, an up-to-date capitalization table, the most recent version of the investment agreements, documents relating to subsequent financing
and a copy of the official articles of association or other constitutional documents of the Group Companies. In addition, the Company shall provide to Ascendis such information and financial statements of the Group Companies and provide access to
personnel reasonably requested by Ascendis in order for Ascendis to timely comply with applicable disclosure and financial and tax reporting requirements. Notwithstanding the foregoing, the Company or any of the Group Companies shall not be
obligated pursuant to this Section 1.1(a)(v) to provide access to (x) any information that it reasonably and in good faith considers to be a trade secret and the disclosure of which

  
 2 

 
would adversely affect the interest of the Group Companies, (y) any confidential information unless covered by an enforceable confidentiality agreement, in form reasonably acceptable to the
Company, or (z) any information the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. The rights set forth above shall be collectively referred to as the “Information
Rights”. 
 All financial statements to be provided to any Rights Holder pursuant to this Section 1.1(a)
shall be in English and shall include an income statement, a balance sheet, a cash flow statement for the relevant period as well as for the fiscal year to-date and shall be prepared in conformance with the
PRC Generally Accepted Accounting Principles (the “PRC GAAP”) with respect to the Group Companies in the PRC, or the International Financial Reporting Standards (the “IFRS”) with respect to the Company and the Group
Company outside of the PRC. 
 For the purpose of this Agreement, a “Competitor” means any Person that engages directly or
indirectly in the Competing Business, and for the avoidance of doubt, a Competitor shall not include (x) Ascendis to the extent it complies with its relevant obligations under Section 9.6 of this Agreement;
(y) any other Investor that is a Party to this Agreement as of the date hereof or any of its Affiliates (as defined below); and (z) any other institutional investment fund, private equity or venture capital fund, collective investment
vehicle or similar investment organization that, together with its Affiliates, does not hold more than [***] percent ([***]%) of the outstanding equity securities (or other securities convertible into or exchangeable or exercisable for equity
securities) in any Person (other than any Group Company) engaged in the Competing Business and is not an Affiliate of any Person (other than any Group Company) engaged in the Competing Business. 

(b) Inspection Rights. The Company further covenants and agrees that, commencing on the date of this Agreement, each Rights Holder shall
have (i) the right to inspect facilities, records and books of the Group Companies at any time during regular working hours upon reasonable prior notice to the Company, (ii) the right to discuss the business, operations and conditions of
the Group Companies with their respective directors, officers, employees, accountants, legal counsel, financial advisors, and investment bankers, and (iii) the right to dispatch auditing personnel of its own or hire independent auditors to
audit the books and records of the Group Companies as needed (the “Inspection Rights”). Such auditing personnel or independent auditors shall have access to all financial statements, financial records, original receipts and other
documents of the Group Companies. Such audit shall not be conducted more than two (2) times per year. The Company shall, and shall cause the Group Companies to provide necessary assistance for such audit. The Investor that hires an independent
auditor shall bear the cost of such auditor. Notwithstanding the foregoing, the Company or any of the Group Companies shall not be obligated pursuant to this Section 1.1(b) to provide access to (x) any information that
it reasonably and in good faith considers to be a trade secret and the disclosure of which would adversely affect the interest of the Group Companies, (y) any confidential information unless covered by an enforceable confidentiality agreement,
in form reasonably acceptable to the Company, or (z) any information the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

1.2 Board of Directors. The Second Amended and Restated Memorandum and Articles of Association of the Company (the “Restated
Articles”) shall provide that the board of directors of the Company (the “Board”, each director of the Board, a “Director” and collectively, the “Directors”) shall consist of six
(6) members, which number of members shall not be changed except pursuant to an amendment to the Restated Articles. Effective from the date hereof, 

  
 3 

 (a) Ascendis shall be entitled to appoint two (2) Directors, who shall initially be Jan
Moller Mikkelsen and Michael Wolff Jensen (each, an “Ascendis Director,” and collectively, the “Ascendis Directors”), and the Ascendis Directors can only be removed by Ascendis; one of the Ascendis Directors shall
serve as the chairman of the Board (the “Chairman”), and in the case of an equality of votes, the Chairman shall have a casting vote, 

(b) Vivo Capital shall be entitled to appoint two (2) Directors, who shall initially be Shan FU and Dandan DONG (each, a “Vivo
Capital Director,” and collectively, the “Vivo Capital Directors,” together with the Ascendis Directors, the “Series A Directors”) and shall be entitled to appoint one (1) such Director as a member to
any committee of the Board, and the Vivo Capital Directors can only be removed by Vivo Capital, 
 (c) the person then serving as the Chief
Executive Officer of the Company shall be appointed as a Director of the Company (the “CEO Director”), provided that if for any reason the CEO Director shall cease to serve as the Chief Executive Officer of the Company, the Majority
Preferred Shareholders shall (i) remove the former Chief Executive Officer of the Company from the Board if such person has not resigned as a member of the Board; and (ii) elect such person’s replacement as Chief Executive Officer of
the Company as the new CEO Director, and 
 (d) so long as Sequoia continues to hold at least [***] Series B Preferred Shares (as adjusted
for share dividends, subdivisions, consolidations, splits, combinations, recapitalizations or similar events), Sequoia shall be entitled to appoint one (1) Director, who shall initially be Yibo CAO (the “Series B Director”,
together with the Series A Directors, collectively, the “Investor Directors” and each an “Investor Director”), and the Series B Director can only be removed by Sequoia for so long as Sequoia is entitled to appoint
the Series B Director. 
 A meeting of Directors is duly constituted for all purposes if at the commencement of the meeting there are
present in person or by alternate such number of Directors not less than a majority of the Directors of the Company, which Directors in each case shall include at least two-thirds (2/3) of the Investor
Directors including the Series B Director. If within two (2) hours from the time appointed for the meeting a quorum is not present, the meeting shall stand adjourned to the same time and place three (3) Business Days later or such other
place as the Directors by unanimous consent may determine, and if at the adjourned meeting a quorum is not present within two (2) hours from the time appointed for the meeting and if a requisite quorum is not achieved based on the failure to
attend such meeting by any Investor Director, then the quorum at such adjourned meeting shall be a majority of the Directors then in office, which for the avoidance of doubt may include the CEO Director. The Company shall reimburse the Directors for
all reasonable out-of-pocket expenses incurred in connection with attending any meetings of the Board and any committee thereof. Notwithstanding the foregoing, if a
majority of the Series A Directors or the Series B Director is not present at such adjourned meeting, no resolution may be adopted at such adjourned meeting with respect to the matters set forth in Section 7.22(A) or
Section 7.2(B), as applicable, but the adoption of the resolution with respect to such matters shall be deferred to a second adjourned meeting, which shall be held at the same time and place two (2) Business Days later
or such other place as the Directors by unanimous consent may determine, and if a majority of the Series A Directors or the Series B Director, as applicable, is still not present at such second adjourned meeting, the affirmative vote or written
consent of a majority of the Series A Directors or the Series B Director, as applicable, for such matters shall no longer be required for the purpose of adopting the resolutions of the Board or any board of directors of any subsidiaries (if
applicable) in connection with the matters set forth in Section 7.22(A) or Section 7.2(B), as applicable. 

  
 4 

 1.3 Observers. 

(a) Vivo Capital shall be entitled to appoint one (1) observer (an “Observer”) to attend all meetings of the Board in a non-voting, observer capacity, and to receive concurrently with the members of the Board all notices of Board meetings (and copies of materials distributed at or in connection with Board meetings);
provided, however, that the Observer shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude the Observer from any meeting
or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such
Observer is a Competitor. 
 (b) Ascendis shall be entitled to appoint one (1) Observer to attend all meetings of the Board in a non-voting, observer capacity, and to receive concurrently with the members of the Board all notices of Board meetings (and copies of materials distributed at or in connection with Board meetings);
provided, however, that the Observer shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude the Observer from any
meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if
such Observer is a Competitor. 
 (c) So long as Sofinnova continues to hold at least [***] Preferred Shares (as adjusted for share
dividends, subdivisions, consolidations, splits, combinations, recapitalizations or similar events), Sofinnova shall be entitled to appoint one (1) Observer to attend all meetings of the Board in a
non-voting, observer capacity, and to receive concurrently with the members of the Board all notices of Board meetings (and copies of materials distributed at or in connection with Board meetings);
provided, however, that the Observer shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude the Observer from any
meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if
such Observer is a Competitor. 
 (d) So long as Sherpa continues to hold at least [***] Series B Preferred Shares (as adjusted for share
dividends, subdivisions, consolidations, splits, combinations, recapitalizations or similar events), Sherpa shall be entitled to appoint one (1) Observer to attend all meetings of the Board in a
non-voting, observer capacity, and to receive concurrently with the members of the Board all notices of Board meetings (and copies of materials distributed at or in connection with Board meetings);
provided, however, that the Observer shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude the Observer from any
meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if
such Observer is a Competitor. 

  
 5 

 1.4 Board of Directors of Subsidiaries. The size and composition of the board of
directors of any subsidiary of the Company, whether now in existence or formed in the future (the “Subsidiaries”), which is wholly owned directly or indirectly by the Company, shall mirror the Board to the extent practicable, as
soon as possible after the Closing or the formation of such relevant Subsidiary, as applicable. In the event one or more Ascendis Directors is appointed to serve on the board of directors of the WFOE, one Ascendis Director shall serve as the
chairman of the board of directors of the WFOE and have a casting vote in the case of an equality of votes to the extent permitted under the applicable laws. 

1.5 Voting Agreement. Each Party agrees that it shall vote all of its Shares (or give shareholders’ consent) in such manner that
gives effect to the provisions of this Agreement, including without limitation to cause the Board to be constituted in accordance with Section 1.2. 

1.6 Termination. The provisions set forth under this Section 1 shall terminate upon the earliest to occur of
(i) the consummation of the Qualified Initial Public Offering (as defined below), (ii) the consummation of an IPO (as defined below) in a Recognized Exchange (as defined below) duly approved by the Board where all Preferred Shares are converted
into Ordinary Shares, or where such provisions are required to be terminated by applicable laws or stock exchange requirements; or (iii) the closing of a Deemed Liquidation Event (as defined in the Restated Articles). 

2. REGISTRATION RIGHTS. 
 2.1
Applicability of Rights. The Holders (as defined below) shall be entitled to the following rights with respect to any proposed public offering of the Company’s Ordinary Shares in the United States and shall be entitled to reasonably
equivalent or analogous rights with respect to any other offering of the Company’s securities in the Hong Kong SAR or any other jurisdiction in which the Company undertakes to publicly offer or list such securities for trading on a recognized
securities exchange. 
 2.2 Definitions. For purposes of this Section 2: 

(a) Registration. The terms “register,” “registered,” and “registration” refer to a
registration effected by filing a registration statement which is in a form which complies with, and is declared effective by the SEC (as defined below) in accordance with, the Securities Act of 1933, as amended to date (the “Securities
Act”). 
 (b) Registrable Securities. The term “Registrable Securities” means: (1) any Ordinary Shares
of the Company issued or issuable pursuant to conversion of any issued and outstanding shares of Preferred Shares, (2) any Ordinary Shares issued (or issuable upon the conversion or exercise of any warrant, right or other security which is
issued) as a dividend or other distribution with respect to, or in exchange for or in replacement of, any Preferred Shares described in clause (1) of this subsection (b), and (3) any other Ordinary Shares of the Company owned or hereafter
acquired by the Investors. Notwithstanding the foregoing, “Registrable Securities” shall exclude any Registrable Securities sold by a person in a transaction in which rights under this Section 2 are not
validly assigned in accordance with this Agreement, and any Registrable Securities which are sold in a registered public offering under the Securities Act or analogous statute of another jurisdiction, or sold pursuant to Rule 144 promulgated under
the Securities Act or analogous rule of another jurisdiction. 

  
 6 

 (c) Registrable Securities Then Outstanding. The number of shares of
“Registrable Securities then Outstanding” shall mean the number of Ordinary Shares of the Company that are Registrable Securities and are then issued and outstanding, issuable upon conversion of Preferred Shares then issued and
outstanding, or issuable upon conversion or exercise of any warrant, right or other security then outstanding. 
 (d) Holder. For
purposes of this Section 2, the term “Holder” means any person owning or having the rights to acquire Registrable Securities or any permitted assignee of record of such Registrable Securities to whom rights
under this Section 2 have been duly assigned in accordance with this Agreement. 
 (e) Form F-3. The term “Form F-3” means such respective form under the Securities Act or any successor registration form under the Securities Act subsequently
adopted by the SEC which permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

(f) SEC. The term “SEC” or “Commission” means the U.S. Securities and Exchange Commission. 

(g) Registration Expenses. The term “Registration Expenses” shall mean all expenses incurred by the Company in
complying with Sections 2.3, 2.4 and 2.5 hereof, including, without limitation, all registration and filing fees, printing expenses, fees, and disbursements of counsel for the Company, reasonable fees and
disbursements, not to exceed US$30,000, of one special counsel for all the Holders, “blue sky” fees and expenses, fees and expenses charged by share registrar and depository agent and the expense of any special audits incident to or
required by any such registration (but excluding the compensation of regular employees of the Company which shall be paid in any event by the Company). 

(h) Selling Expenses. The term “Selling Expenses” shall mean all underwriting discounts and selling commissions
applicable to the sale of Registrable Securities pursuant to Sections 2.3, 2.4 and 2.5 hereof. 
 (i) Exchange
Act. The term “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, and any successor statute. 

2.3 Demand Registration. 

(a) Request by Holders. If the Company shall, at any time after the earlier of (i) three (3) years after the Closing or
(ii) six (6) months following the taking effect of a registration statement for the initial underwritten public offering of the securities of the Company (the “IPO”), receive a written request from the Holders of at least [***]
percent ([***]%) of the Registrable Securities then Outstanding that the Company file a registration statement under the Securities Act on any internationally recognized exchange that is acceptable to such requesting Holders pursuant to this
Section 2.3 covering the registration of the Registrable Securities then Outstanding subject to a minimum offering size of US$15,000,000, then the Company shall, within ten (10) Business Days of the receipt of such
written request, give written notice of such request (the “Request Notice”) to all Holders, and use its best efforts to effect, as soon as practicable, the registration under the Securities Act of all Registrable Securities that the
Holders request to be registered and included in such registration by written notice given by such Holders to the Company within twenty (20) days after receipt of the Request Notice, subject only to the limitations of this
Section 2.3; provided 

  
 7 

 
that the Company shall not be obligated to effect any such registration if the Company has, within the six (6) month period preceding the date of such request, already effected a
registration under the Securities Act pursuant to this Section 2.3 or Section 2.5 or in which the Holders had an opportunity to participate pursuant to the provisions of
Section 2.4, other than a registration from which the Registrable Securities of the Holders have been excluded (with respect to all or any portion of the Registrable Securities the Holders requested be included in such
registration) pursuant to the provisions of Section 2.4(a). The Company shall be obligated to effect no more than two (2) Registration pursuant to this Section 2.3. A registration shall not be
counted as “effected” for purposes of this Section 2.3(a) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders (as defined below) withdraw
their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn registration
statement shall be counted as “effected” for purposes of this Section 2.3(a). For purposes of this Agreement, reference to registration of securities under the Securities Act and the Exchange Act shall be deemed
to mean the equivalent registration in a jurisdiction other than the United States as designated by such Holders, it being understood and agreed that in each such case all references in this Agreement to the Securities Act, the Exchange Act and
rules, forms of registration statements and registration of securities thereunder, U.S. law and the SEC, shall be deemed to refer, to the equivalent statutes, rules, forms of registration statements, registration of securities and laws of and
equivalent government authority in the applicable non-U.S. jurisdiction. 
 (b) Underwriting.
If the Holders initiating the registration request under this Section 2.3 (the “Initiating Holders”) intend to distribute the Registrable Securities covered by their request by means of an underwriting,
then they shall so advise the Company as a part of their request made pursuant to this Section 2.3 and the Company shall include such information in the Request Notice. In such event, the right of any Holder to include its
Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a
majority in interest of the Initiating Holders and such Holder) to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall enter into an underwriting agreement in customary form with the
managing underwriter or underwriters selected for such underwriting by the Holders of a majority of the Registrable Securities being registered and reasonably acceptable to the Company. Notwithstanding any other provision of this
Section 2.3, if the underwriter(s) advise(s) the Company in writing that marketing factors require a limitation of the number of securities to be underwritten, then the Company shall so advise all Holders of Registrable
Securities which would otherwise be registered and underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be reduced as required by the underwriter(s) and allocated among the Holders of
Registrable Securities on a pro rata basis according to the number of Registrable Securities then Outstanding held by each Holder requesting registration (including the Initiating Holders); provided, however, that the number of shares
of Registrable Securities to be included in such underwriting and registration shall not be reduced unless all other securities are first entirely excluded from the underwriting and registration including, without limitation, all shares that are not
Registrable Securities and are held by any other person, including, without limitation, any person who is an employee, officer or director of the Company or any Subsidiary of the Company; provided further, that at least twenty-five
percent (25%) of Registrable Securities requested by the Holders to be included in such underwriting and registration shall be so included. If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom
by written notice to the Company and the underwriter(s), delivered at least ten (10) business days prior to the effective date of the registration statement. Any Registrable Securities excluded or withdrawn from such underwriting shall be
excluded and withdrawn from the registration. 

  
 8 

 2.4 Piggyback Registrations. 

(a) The Company shall notify all Holders of Registrable Securities in writing at least thirty (30) days prior to filing any registration
statement under the Securities Act for purposes of effecting a public offering of securities of the Company (including, but not limited to, registration statements relating to secondary offerings of securities of the Company, but excluding
registration statements relating to any employee benefit plan or a corporate reorganization), and shall afford each such Holder an opportunity to include in such registration statement all or any part of the Registrable Securities then held by such
Holder. Each Holder desiring to include in any such registration statement all or any part of the Registrable Securities held by it shall within twenty (20) days after receipt of the above-described notice from the Company, so notify the
Company in writing, and in such notice shall inform the Company of the number of Registrable Securities such Holder wishes to include in such registration statement. If a Holder decides not to include all of its Registrable Securities in any
registration statement thereafter filed by the Company, such Holder shall nevertheless continue to have the right to include any Registrable Securities in any subsequent registration statement or registration statements as may be filed by the
Company with respect to offerings of its securities, all upon the terms and conditions set forth herein. No Holder of Registrable Securities shall be granted piggyback registration rights superior to those of the Holders of the Preferred Shares
without the consent in writing of the Holders of at least fifty percent (50%) of the Registrable Securities. 
 (b) Underwriting. If a
registration statement under which the Company gives notice under this Section 2.4 is for an underwritten offering, then the Company shall so advise the Holders of Registrable Securities. In such event, the right of any
such Holder’s Registrable Securities to be included in a registration pursuant to this Section 2.4 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s
Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the managing
underwriter or underwriters selected for such underwriting. Notwithstanding any other provision of this Agreement but subject to Section 2.13, if the managing underwriter(s) determine(s) in good faith that marketing factors
require a limitation of the number of shares to be underwritten, then the managing underwriter(s) may exclude shares from the registration and the underwriting, and the number of shares that may be included in the registration and the underwriting
shall be allocated, first, to the Company, second, to each of the Holders requesting inclusion of their Registrable Securities in such registration statement on a pro rata basis based on the total number of shares of Registrable
Securities then held by each such Holder, and third, to holders of other securities of the Company; provided, however, that the right of the underwriter(s) to exclude shares (including Registrable Securities) from the
registration and underwriting as described above shall be restricted so that (i) the number of Registrable Securities included in any such registration is not reduced below twenty percent (20%) of the aggregate number of shares of Registrable
Securities for which inclusion has been requested; and (ii) all shares that are not Registrable Securities and are held by any other person, including, without limitation, any person who is an employee, officer or director of the Company (or
any subsidiary of the 

  
 9 

 
Company) shall first be excluded from such registration and underwriting before any Registrable Securities are so excluded. If any Holder disapproves of the terms of any such underwriting, such
Holder may elect to withdraw therefrom by written notice to the Company and the underwriter(s), delivered at least ten (10) business days prior to the effective date of the registration statement. Any Registrable Securities excluded or
withdrawn from such underwriting shall be excluded and withdrawn from the registration. 
 (c) Not Demand Registration. Registration
pursuant to this Section 2.4 shall not be deemed to be a demand registration as described in Section 2.3 above. There shall be no limit on the number of times the Holders may request registration
of Registrable Securities under this Section 2.4. 
 2.5 Form F-3.
If at any time when it is eligible to use a Form F-3 registration statement the Company shall receive from the Holders of at least thirty percent (30%) of the Registrable Securities then Outstanding a written
request or requests that the Company effect a registration on Form F-3 and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders,
then the Company will: 
 (a) Notice. Promptly give written notice of the proposed registration and the Holder’s or Holders’
request therefor, and any related qualification or compliance, to all other Holders of Registrable Securities; and 
 (b)
Registration. As soon as practicable, effect such registration and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holders or
Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within twenty
(20) days after the Company provides the notice contemplated by Section 2.5(a); provided, however, that the Company shall not be obligated to effect any such registration, qualification or compliance
pursuant to this Section 2.5: 
 (i) if the Holders, together with the holders of any other securities of the
Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than US$5,000,000; 

(ii) if the Company shall furnish to the Holders a certificate signed by the President or Chief Executive Officer of the Company stating that
in the good faith judgment of the Board, it would be materially detrimental to the Company and its shareholders for such Form F-3 registration to be effected at such time, in which event the Company shall have
the right to defer the filing of the Form F-3 registration statement no more than once during any twelve (12) month period for a period of not more than sixty (60) days after receipt of the request
of the Holder or Holders under this Section 2.5; provided that the Company shall not register any of its other shares during such sixty (60) day period; A registration right under this
Section 2.5 shall not be deemed to have been exercised until such deferred registration shall have been effected; 

(iii) if the Company has, within the twelve (12) month period preceding the date of such request, already effected one
(1) registration on Form F-3; 

  
 10 

 (iv) if the Company has, within the twelve (12) month period preceding the date of
such request, already effected two (2) registrations under the Securities Act other than a registration from which the Registrable Securities of Holders have been excluded (with respect to all or any portion of the Registrable Securities the
Holders requested be included in such registration) pursuant to the provisions of Sections 2.3(b) and 2.4(a); or 
 (v) in any
particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance. 

Subject to the foregoing, the Company shall file a Form F-3 registration statement covering the Registrable Securities
and other securities so requested to be registered as soon as practicable after receipt of the request or requests of the Holders. 
 (c)
Not Demand Registration. Form F-3 registrations shall not be deemed to be demand registrations as described in Section 2.3 above. Except as otherwise provided herein, there
shall be no limit on the number of times the Holders may request registration of Registrable Securities under this Section 2.5. 

2.6 Expenses. All Registration Expenses incurred in connection with any registration pursuant to Sections 2.3, 2.4 or
2.5 (but excluding Selling Expenses) shall be borne by the Company. Each Holder participating in a registration pursuant to Sections 2.3, 2.4 or 2.5 shall bear such Holder’s proportionate share (based on the total
number of shares sold in such registration other than for the account of the Company) of all Selling Expenses or other amounts payable to underwriter(s) or brokers, in connection with such offering by the Holders. Notwithstanding the foregoing, the
Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.3 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the
Registrable Securities to be registered, unless the Holders of a majority of the Registrable Securities then Outstanding agree that such registration constitutes the use by the Holders of one (1) demand registration pursuant to
Section 2.3; provided further, however, that if at the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business, or prospects of the Company not known to
the Holders at the time of their request for such registration and have withdrawn their request for registration with reasonable promptness after learning of such material adverse change, then the Holders shall not be required to pay any of such
expenses and such registration shall not constitute the use of a demand registration pursuant to Section 2.3. 

2.7 Obligations of the Company. Whenever required to effect the registration of any Registrable Securities under this Agreement the
Company shall, as expeditiously as reasonably possible: 
 (a) Registration Statement. Prepare and file with the SEC a registration
statement with respect to such Registrable Securities and use its best efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep
such registration statement effective for a period of up to ninety (90) days or, in the case of Registrable Securities registered under Form F-3 in accordance with Rule 415 under the Securities Act or a
successor rule, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such ninety (90) day period shall be extended for a period of time equal to the period any
Holder refrains from selling any securities included in such registration at the request of the underwriter(s), and (ii) in the case of any registration of Registrable Securities on Form F-3 which are
intended to be offered on a continuous or delayed basis, such ninety (90) day period shall be extended, if necessary, to keep the registration statement effective until all such Registrable Securities are sold. 

  
 11 

 (b) Amendments and Supplements. Prepare and file with the SEC such amendments and
supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by
such registration statement. 
 (c) Prospectuses. Furnish to the Holders such number of copies of a prospectus, including a
preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of the Registrable Securities owned by them that are included in such
registration. 
 (d) Blue Sky. Use its best efforts to register and qualify the securities covered by such registration statement
under such other securities or “blue sky” laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do
business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act. 

(e) Underwriting. In the event of any underwritten public offering, enter into and perform its obligations under an underwriting
agreement in usual and customary form, with the managing underwriter(s) of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. 

(f) Notification. Notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus
relating thereto is required to be delivered under the Securities Act of (i) the issuance of any stop order by the SEC in respect of such registration statement, or (ii) the happening of any event as a result of which the prospectus
included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of
the circumstances then existing. 
 (g) Opinion and Comfort Letter. Furnish, at the request of any Holder requesting registration of
Registrable Securities, on the date that such Registrable Securities are delivered to the underwriter(s) for sale, if such securities are being sold through underwriters, or, if such securities are not being sold through underwriters, on the date
that the registration statement with respect to such securities becomes effective, (i) an opinion, dated as of such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily
given to underwriters in an underwritten public offering and reasonably satisfactory to a majority in interest of the Holders requesting registration, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable
Securities and (ii) letters dated as of (x) the effective date of the registration statement covering such Registrable Securities and (y) the closing date of the offering, from the independent certified public accountants of the
Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering and reasonably satisfactory to a majority in interest of the Holders requesting registration,
addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities. 

  
 12 

 2.8 Furnish Information. It shall be a condition precedent to the obligations of the
Company to take any action pursuant to Sections 2.3, 2.4 or 2.5 that the selling Holders shall furnish to the Company such information regarding themselves, the Registrable Securities held by them and the intended method of
disposition of such securities as shall be required to timely effect the Registration of their Registrable Securities. 
 2.9
Indemnification. In the event any Registrable Securities are included in a registration statement under Sections 2.3, 2.4 or 2.5: 

(a) By the Company. To the extent permitted by law and the Restated Articles, the Company will indemnify and hold harmless each Holder,
its partners, officers, directors, legal counsel, any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act,
against any losses, claims, damages, or liabilities (joint or several) to which they may become subject under the Securities Act, the Exchange Act, or other United States federal or state law, insofar as such losses, claims, damages, or liabilities
(or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a “Violation”): 

(i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement, including any preliminary
prospectus or final prospectus contained therein or any amendments or supplements thereto; 
 (ii) the omission or alleged omission to state
therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or 
 (iii) any violation
or alleged violation by the Company of the Securities Act, the Exchange Act, any United States federal or state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any United States federal or state
securities law in connection with the offering covered by such registration statement; 
 and the Company will reimburse each such Holder, its partner,
officer, director, legal counsel, underwriter or controlling person for any legal or other expenses reasonably incurred by them, as such expenses are incurred, in connection with investigating or defending any such loss, claim, damage, liability or
action; provided, however, that the indemnity agreement contained in this subsection 2.9(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the
consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation which
occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by such Holder, partner, officer, director, legal counsel, underwriter or controlling person of such Holder. 

  
 13 

 (b) By Selling Holders. To the extent permitted by law, each selling Holder will, if
Registrable Securities held by Holder are included in the securities as to which such registration qualifications or compliance is being effected, indemnify and hold harmless the Company, each of its directors, each of its officers who has signed
the registration statement, each person, if any, who controls the Company within the meaning of the Securities Act, any underwriter and any other Holder selling securities under such registration statement or any of such other Holder’s
partners, directors, officers, legal counsel or any person who controls such Holder within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages or liabilities (joint or several) to which the Company or any such
director, officer, legal counsel, controlling person, underwriter or other such Holder, partner or director, officer or controlling person of such other Holder may become subject under the Securities Act, the Exchange Act or other United States
federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance
upon and in conformity with written information furnished by such Holder expressly for use in connection with such registration; and each such Holder will reimburse any legal or other expenses reasonably incurred by the Company or any such director,
officer, controlling person, underwriter or other Holder, partner, officer, director or controlling person of such other Holder in connection with investigating or defending any such loss, claim, damage, liability or action; provided,
however, that the indemnity agreement contained in this subsection 2.9(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder,
which consent shall not be unreasonably withheld; and provided, further, that in no event shall any indemnity under this Section 2.9(b) together with any amount contributed pursuant to
Section 2.9(d) below exceed the net proceeds (net of any Selling Expenses paid by such Holder) received by such Holder in the registered offering out of which the applicable Violation arises, except in the case of willful
misconduct or fraud by such Holder. 
 (c) Notice. Promptly after receipt by an indemnified party under this
Section 2.9 of notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Section 2.9, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly
with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party shall have the right to retain its own counsel, with the
fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential conflict of interests between such indemnified
party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of
liability to the indemnified party under this Section 2.9 to the extent the indemnifying party is prejudiced as a result thereof, but the omission to so deliver written notice to the indemnifying party will not relieve it
of any liability that it may have to any indemnified party otherwise than under this Section 2.9. 
 (d)
Contribution. In order to provide for just and equitable contribution to joint liability under the Securities Act in any case in which either (i) any indemnified party makes a claim for indemnification pursuant to this
Section 2.9 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such
indemnification may not be enforced in such case notwithstanding the fact that this Section 2.9 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of
any indemnified party in circumstances for which indemnification is provided under 

  
 14 

 
this Section 2.9; then, and in each such case, the indemnified party and the indemnifying party will contribute to the aggregate losses, claims, damages or liabilities
to which they may be subject (after contribution from others) in such proportion so that a Holder (together with its related persons) is responsible for the portion represented by the percentage that the public offering price of its Registrable
Securities offered by and sold under the registration statement bears to the public offering price of all securities offered by and sold under such registration statement, and the Company and other selling Holders are responsible for the remaining
portion. The relative fault of the indemnifying party and of the indemnified party shall be determined by a court of law by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state
a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission;
provided, however, that, in any such case: (A) no Holder will be required to contribute any amount in excess of the net proceeds to such Holder from the sale of all such Registrable Securities offered and sold by such Holder
pursuant to such registration statement; and (B) no person or entity guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person
or entity who was not guilty of such fraudulent misrepresentation. 
 (e) Survival; Consents to Judgments and Settlements. The
obligations of the Company and Holders under this Section 2.9 shall survive until the fifth (5th) anniversary of the completion of any offering of Registrable Securities in a registration statement, regardless of the
expiration of any statutes of limitation or extensions of such statutes. No indemnifying party, in the defense of any such claim or litigation, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into
any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. 

2.10 No Registration Rights to Third Parties. Without the prior written consent of the holders of at least sixty percent (60%) of the
Registrable Securities then outstanding, the Company covenants and agrees that it shall not grant, or cause or permit to be created, for the benefit of any person or entity any registration rights of any kind (whether similar to the demand,
“piggyback” or Form F-3 registration rights described in this Section 2, or otherwise) relating to any securities of the Company which are senior to, or on a parity with,
those granted to the Holders of Registrable Securities. 
 2.11 Rule 144 Reporting. With a view to making available to the Holders the
benefits of certain rules and regulations of the SEC which may at any time permit the sale of the Registrable Securities to the public without registration or pursuant to a registration on Form F-3, after such
time as a public market exists for the Ordinary Shares, the Company agrees to: 
 (a) Make and keep public information available, as those
terms are understood and defined in Rule 144 under the Securities Act, at all times after the effective date of the first registration under the Securities Act filed by the Company for an offering of its securities to the general public; 

(b) File with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act
(at any time after it has become subject to such reporting requirements); and 

  
 15 

 (c) So long as a Holder owns any Registrable Securities, to furnish to such Holder forthwith
upon request (i) a written statement by the Company as to its compliance with the reporting requirements of Rule 144 (at any time after ninety (90) days after the effective date of the Company’s initial public offering), the
Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), or its qualification as a registrant whose securities may be resold pursuant to Form F-3 (at any
time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company, and (iii) such other reports and documents of the Company as a Holder may reasonably request in availing itself of any rule or regulation of
the SEC that permits the selling of any such securities without registration or pursuant to Form F-3. 

2.12 Market Stand-Off. Each Party agrees that, so long as it holds any voting securities of the
Company, upon request by the Company or the underwriters managing the initial public offering of the Company’s securities, it will not sell or otherwise transfer or dispose of any securities of the Company held immediately before the
effective date of the registration statement for such offering (other than those permitted to be included in the registration and other transfers to Affiliates permitted by law) without the prior written consent of the Company or such underwriters,
as the case may be, for a period of time specified by the representative of the underwriters not to exceed 180 days from the effective date of the registration statement covering such initial public offering or the pricing date of such offering as
may be requested by the underwriters. The Company shall use commercially reasonable efforts to take all steps to shorten such lock-up period. The foregoing provision of this
Section 2.12 shall not apply to the sale of any securities of the Company to an underwriter pursuant to any underwriting agreement, and shall only be applicable to the Holders if all shareholders owning more than five
percent (5%) of the Company’s outstanding Ordinary Shares (on an as-converted basis) are subject to the same restrictions, and if the Company or any underwriter releases any other shareholder from his,
her or its sale restrictions so undertaken, then each Holder shall be notified prior to such release and shall itself be simultaneously released to the same proportional extent. The Company shall require all future acquirers of the Company’s
securities to execute prior to a Qualified Initial Public Offering a market stand-off agreement containing substantially similar provisions as those contained in this Section 2.12.

 2.13 Termination. The registration rights in this Section 2 shall terminate upon the earliest to occur of
(i) the closing of a Deemed Liquidation Event; (ii) such time as Rule 144 or another similar exemption under the Securities Act or other applicable securities laws is available for the sale of all of such Holder’s shares without
registration; or (iii) the third (3rd) anniversary of a firm-commitment underwritten initial public offering by the Company of its Ordinary Shares or a reverse merger of the Company with a
listed company, on a reputable securities exchange in the United States, Hong Kong or PRC (excluding the National Equities Exchange And Quotations of the PRC), or any other jurisdiction, including without limitations, the New York Stock Exchange or
the Nasdaq Global Market in the United States and the Main Board of the Hong Kong Stock Exchange (each, a “Recognized Exchange”), with a per share price of at least US$[***] (subject to adjustments for share dividends, splits,
combinations, recapitalization and similar events) and net proceeds to the Company of at least US$[***] (the “Qualified Initial Public Offering”). 

  
 16 

 3. RIGHT OF PARTICIPATION. 

3.1 General. Each holder of Preferred Shares, including each holder of Preferred Shares to which rights under this
Section 3 have been duly assigned in accordance with Section 5 (hereinafter referred to as a “Participation Rights Holder”), shall have the preemptive right to purchase such
Participation Rights Holder’s Pro Rata Share (as defined below), of all (or any part) of any New Securities (as defined in Section 3.3) that the Company may from time to time issue after the date of this Agreement (the
“Right of Participation”). A Participation Rights Holder shall be entitled to apportion the Right of Participation hereby granted to it in such proportions as it deems appropriate, among (i) itself and (ii) its Affiliates;
provided that each such Affiliate (x) is not a Competitor, and (y) agrees to enter into this Agreement. 
 3.2 Pro Rata
Share. A Participation Rights Holder’s “Pro Rata Share” for purposes of the Right of Participation is the ratio of (a) the number of Ordinary Shares (calculated on a fully-diluted and
as-converted basis) held by such Participation Rights Holder, to (b) the total number of Ordinary Shares of the Company then outstanding (calculated on a fully-diluted and
as-converted basis) held by all the Participation Rights Holders immediately prior to the issuance of the New Securities giving rise to the Right of Participation. 

3.3 New Securities. “New Securities” shall mean any Preferred Shares, Ordinary Shares,
Non-voting Ordinary Shares or other voting shares of the Company and rights, options or warrants to purchase such Preferred Shares, Ordinary Shares, Non-voting Ordinary
Shares and securities of any type whatsoever that are, or may become, convertible or exchangeable into such Preferred Shares, Ordinary Shares, Non-voting Ordinary Shares or other voting shares,
provided, however, that the term “New Securities” shall not include the Exempted Securities (as defined in the Restated Articles). 

3.4 Procedures. 
 (a) First
Participation Notice. In the event that the Company proposes to undertake an issuance of New Securities (in a single transaction or a series of related transactions), it shall give to each Participation Rights Holder written notice of its
intention to issue New Securities (the “First Participation Notice”), describing the amount and type of New Securities, the price and the general terms upon which the Company proposes to issue such New Securities. Each Participation
Rights Holder shall have twenty (20) Business Days from the date of receipt of any such First Participation Notice (the “First Participation Period”) to agree in writing to purchase such Participation Rights Holder’s Pro
Rata Share of such New Securities for the price and upon the terms and conditions specified in the First Participation Notice by giving written notice to the Company and stating therein the quantity of New Securities to be purchased (not to exceed
such Participation Rights Holder’s Pro Rata Share). If any Participation Rights Holder fails to so agree in writing within such twenty (20) Business Days period to purchase such Participation Rights Holder’s full Pro Rata Share of an
offering of New Securities, then such Participation Rights Holder shall forfeit the right hereunder to purchase that part of its Pro Rata Share of such New Securities that it did not agree to purchase. 

(b) Second Participation Notice; Oversubscription. If any Participating Rights Holder fails or declines to exercise its Right of
Participation in accordance with subsection (a) above, the Company shall promptly give notice (the “Second Participation Notice”) to other Participating Rights Holders who exercised their Right of Participation (the
“Right Participants”) in accordance with subsection (a) above. Each Right Participant shall have ten (10) Business Days from the date of receipt of the Second Participation Notice (the “Second Participation
Period”) to notify the Company of its desire to purchase more than its Pro Rata Share of the New Securities, stating the number of the additional New Securities it proposes to buy (the “Additional Number”). If, as a result
thereof, such oversubscription exceeds the total number of the remaining New Securities available for purchase, each 

  
 17 

 
oversubscribing Right Participant will be cut back by the Company with respect to its oversubscription to that number of remaining New Securities equal to the lesser of (x) the Additional
Number and (y) the product obtained by multiplying (i) the number of the remaining New Securities available for subscription by (ii) a fraction, the numerator of which is the number of Ordinary Shares (calculated on a fully-diluted
and as-converted basis) held by such oversubscribing Right Participant and the denominator of which is the total number of Ordinary Shares (calculated on a fully-diluted and
as-converted basis) held by all the oversubscribing Right Participants immediately prior to the issuance of the New Securities giving rise to the Right of Participation. 

(c) Each Right Participant who exercises its Right of Participation hereunder by delivering aforesaid notice shall be obligated to buy such
number of New Securities in accordance with the terms of Section 3.4 and the Company shall so notify the Right Participants within ten (10) Business Days following the date of the Second Participation Notice. The
transaction in connection with the New Securities shall be consummated within forty-five (45) days after the expiration of the Second Participation Period. 

3.5 Failure to Exercise. Upon the expiration of the Second Participation Period, the Company shall have ninety days (90) days
thereafter to sell the New Securities described in the First Participation Notice (with respect to the remaining New Securities) at the same or higher price and upon non-price terms not materially more
favorable to the purchasers thereof than specified in the First Participation Notice, provided that the prospective purchaser of such New Securities shall comply with this Agreement and the Restated Articles, as maybe amended from time to time. In
the event that the Company has not issued and sold such New Securities within such ninety days (90) day period, then the Company shall not thereafter issue or sell any New Securities without again first offering such New Securities to the
Participation Rights Holders pursuant to this Section 3. 
 3.6 Termination. The provisions set forth under
this Section 3 shall terminate upon the earliest to occur of (i) the consummation of the Qualified Initial Public Offering, (ii) the consummation of an IPO in a Recognized Exchange duly approved by the Board where
all Preferred Shares are converted into Ordinary Shares, or where such provisions are required to be terminated by applicable laws or stock exchange requirements; or (iii) the closing of a Deemed Liquidation Event. 

4. TRANSFER RESTRICTIONS. 
 4.1 Certain
Definitions. For purposes of this Section 4, “Ordinary Shares” means (i) the Company’s outstanding Ordinary Shares (other than those issued upon conversion of any Preferred Shares), (ii) the
Company’s outstanding Non-voting Ordinary Shares, and (iii) the Ordinary Shares and the Non-voting Ordinary Shares issuable upon exercise of outstanding
options or warrants; “Preferred Shareholder” means the holder of Series A Preferred Shares and/or holder of Series B Preferred Shares of the Company; “Ordinary Shareholder” means a holder of any Ordinary Share of
the Company; and “Shareholder” means a Preferred Shareholder or an Ordinary Shareholder. 
 4.2 Right of First
Refusal. Subject to Section 4.4 and Section 4.5 of this Agreement, if any Ordinary Shareholder proposes to directly or indirectly (including through a holding entity, special purpose vehicle,
or by any similar methods) sell, assign, pledge, hypothecate, transfer, exchange or otherwise encumber or dispose of in any way or otherwise grant any interest or right (“Transfer”) with respect to all or any part of any interest in
any Ordinary 

  
 18 

 
Shares held by it to any third party (each, a “Selling Shareholder”), then such Selling Shareholder shall promptly give written notice (the “Transfer Notice”) to
the Company and each Preferred Shareholder (the “Non-Selling Shareholders”) prior to such Transfer. The Transfer Notice shall describe in reasonable detail the proposed Transfer including,
without limitation, the number of Ordinary Shares to be Transferred (the “Offered Shares”), the nature of such Transfer, the consideration to be paid, and the name and address of each prospective purchaser or transferee. The Company
and the Non-Selling Shareholders may exercise their right of first refusal with respect to the Offered Shares as follows: 

(a) Option of the Company. 

(i) The Company shall have a first option for a period of fifteen (15) Business Days from receipt of the Transfer Notice (the
“Company’s First Refusal Period”) to elect to purchase the Offered Shares at the same price and subject to the same terms and conditions as described in the Transfer Notice (the “Company’s Right of First
Refusal”). The Company may exercise the Company’s Right of First Refusal and purchase all or any portion of the Offered Shares by notifying the Selling Shareholder in writing (the “Company’s First Refusal Notice”)
before expiration of Company’s First Refusal Period as to the number of shares that it wishes to purchase. 
 (ii) In the event that
the Company has declined to exercise its rights to purchase all, or a portion of, the Offered Shares or fails to deliver the Company’s First Refusal Notice within the Company’s First Refusal Period, then the Selling Shareholder shall,
within three (3) days after the expiration of the Company’s First Refusal Period, give each Non-Selling Shareholders a “Secondary Transfer Notice” which shall identify the Offered
Shares with respect to which the Company has declined to purchase or failed to exercise its right of first refusal (the “Remaining Shares”). 

(b) Option of the Preferred Shareholders. 

(i) Each Non-Selling Shareholder shall have an option for a period of twenty (20) Business Days
from receipt of the Secondary Transfer Notice (the “Preferred Shareholders’ First Refusal Period”) to elect to purchase the Remaining Shares at the same price and subject to the same terms and conditions as
described in the Transfer Notice (the “Preferred Shareholders’ Right of First Refusal”). Each Non-Selling Shareholder may exercise the Preferred Shareholders’ Right of
First Refusal and purchase all or any portion of the Remaining Shares by notifying the Selling Shareholder, the Company and each other Non-Selling Shareholder in writing (the “Preferred
Shareholders’ First Refusal Notice”) before expiration of Preferred Shareholders’ First Refusal Period as to the number of shares that it wishes to purchase. The Preferred Shareholders’ First Refusal Notice
shall set forth the number of Remaining Shares that such Non-Selling Shareholder wishes to purchase, which amount shall not exceed the First Refusal Allotment (as defined below) of such Non-Selling Shareholder. 
 (ii) In the event any Non-Selling
Shareholder elects not to purchase its First Refusal Allotment of the Remaining Shares available under Section 4.2(a)(i) within the Preferred Shareholders’ First Refusal Period, then the Selling Shareholder shall
promptly give written notice (the “Preferred Shareholders’ Overallotment Notice”) to each Non-Selling Shareholder that has elected to purchase all of its First Refusal Allotment of the
Remaining Shares (each a “Fully Participating Preferred Shareholder”), which notice shall set forth the number of Remaining Shares not purchased by the other Non-Selling Shareholders

  
 19 

 
(“Preferred Shareholders’ Overallotment Shares”), and shall offer the Fully Participating Preferred Shareholders the right to acquire its First Refusal Allotment of the
Preferred Shareholders’ Overallotment Shares. Each Fully Participating Preferred Shareholder shall have five (5) Business Days after receipt of the Preferred Shareholders’ Overallotment Notice (the “Preferred
Shareholders’ Overallotment Period”) to deliver a written notice to the Selling Shareholder (the “Participating Preferred Shareholders’ Overallotment Notice”) of its election to purchase its First Refusal
Allotment of the Preferred Shareholders’ Overallotment Shares on the same terms and conditions as set forth in the Transfer Notice, which such Participating Preferred Shareholders’ Overallotment Notice shall also indicate the maximum
number of the Preferred Shareholders’ Overallotment Shares that such Fully Participating Preferred Shareholder will purchase in the event that any other Fully Participating Preferred Shareholder elects not to purchase its First Refusal
Allotment of the Preferred Shareholders’ Overallotment Shares. 
 (c) First Refusal Allotment. Each Non-Selling Shareholder shall have the right to purchase that number of the Remaining Shares or Preferred Shareholders’ Overallotment Shares, as the case may be (the “First Refusal Allotment”),
equivalent to the product obtained by multiplying the aggregate number of the Remaining Shares or Preferred Shareholders’ Overallotment Shares, as the case may be, by a fraction, the numerator of which is the number of Ordinary Shares (on an as-converted basis) held by such Non-Selling Shareholder at the time of the transaction and the denominator of which is the total number of Ordinary Shares (on an as-converted basis) owned by all Non-Selling Shareholders at the time of the transaction who have the right of first refusal to purchase the applicable shares and have elected
to participate in such right of first refusal purchase. A Non-Selling Shareholder shall not have a right to purchase any of the Remaining Shares or Preferred Shareholders’ Overallotment Shares, as
applicable, unless it exercises its right of first refusal within the Preferred Shareholders First Refusal Period or the Preferred Shareholders’ Overallotment Period, as applicable, to purchase up to all of its First Refusal Allotment of the
Remaining Shares or Preferred Shareholders’ Overallotment Shares, as applicable. 
 (d) Purchase Price and Payment. The purchase
price for the Offered Shares to be purchased by the Company and/or the Non-Selling Shareholders exercising their right of first refusal will be the price set forth in the Transfer Notice, but will be payable
as set forth below. If the purchase price in the Transfer Notice includes consideration other than cash, the cash equivalent value of the non-cash consideration will be as previously determined by the Board in
good faith (including affirmative votes of the Series B Director and a majority of the Series A Directors) or by a third party appraisal institution engaged by the Board, which determination will be binding upon the Company, the Selling Shareholder
and the Non-Selling Shareholders, absent fraud or error. The transaction shall be closed within forty-five (45) Business Days following the date of the Transfer Notice and the payment of the purchase
price shall be made by wire transfer or check as directed by the Selling Shareholder. 
 (e) Expiration Notice. Within five
(5) days after the expiration of the Preferred Shareholders’ Overallotment Period, the Company will give written notice (the “First Refusal Expiration Notice”) to the Selling Shareholder and the Non-Selling Shareholders specifying either (i) that all of the Offered Shares were subscribed by the Company and/or the Non-Selling Shareholders exercising their rights
of first refusal, or (ii) that the Company and/or the Non-Selling Shareholders have not subscribed for all of the Offered Shares in which case the First Refusal Expiration Notice will specify the Co-Sale Pro Rata Portion (as defined below) of the remaining Offered Shares for the purpose of the co-sale right of the holders of the Preferred Shares described in
Section 4.3 below. 

  
 20 

 (f) Rights of a Selling Shareholder. If the Company and/or any Non-Selling Shareholder exercises its right of first refusal to purchase the Offered Shares, then, upon the date the notice of such exercise is given by the Company and/or such
Non-Selling Shareholder, the Selling Shareholder will have no further rights as a holder of such Offered Shares except the right to receive payment for such Offered Shares from the Company and/or such Non-Selling Shareholder in accordance with the terms of this Agreement, and the Selling Shareholder will forthwith cause all certificate(s) evidencing such Offered Shares to be surrendered to the Company for
cancellation and deliver to the Company a duly executed share transfer in respect of the Offered Shares to be transferred to the Company and/or such Non-Selling Shareholder, and the Company shall update its
register of members accordingly. 
 4.3 Preferred Shareholder’s Co-Sale
Right. In the event that the Company and the Non-Selling Shareholders have not exercised their right of first refusal with respect to all of the Offered Shares, then the remaining Offered Shares not
subscribed for under the right of first refusal pursuant to Section 4.2 above shall be subject to co-sale rights under this Section 4.3 and each Non-Selling Shareholder who has not exercised any of its right of first refusal with respect to the Offered Shares shall have the right, exercisable upon written notice to the Selling Shareholder, the Company and
each other Non-Selling Shareholder (the “Co-Sale Notice”) within twenty (20) Business Days after receipt of First Refusal Expiration Notice (the
“Co-Sale Right Period”), to participate in such sale of the Offered Shares on the same terms and conditions as set forth in the Transfer Notice. The
Co-Sale Notice shall set forth the number of Ordinary Shares (on as-converted basis) that such participating Non-Selling
Shareholder wishes to include in such sale or transfer, which amount shall not exceed the Co-Sale Pro Rata Portion (as defined below) of such Non-Selling Shareholder. To
the extent one or more of the Non-Selling Shareholder exercise such co-sale right in accordance with the terms and conditions set forth below, the number of Ordinary
Shares that such Selling Shareholder may sell in the transaction shall be correspondingly reduced. The co-sale right of each Non-Selling Shareholder shall be subject to
the following terms and conditions: 
 (a) Co-Sale Pro Rata Portion. Each Non-Selling Shareholder may sell all or any part of that number of Ordinary Shares held by it that is equal to the product obtained by multiplying (x) the aggregate number of the Offered Shares subject to the co-sale right hereunder by (y) a fraction, the numerator of which is the number of Ordinary Shares (on an as-converted basis) owned by such
Non-Selling Shareholder at the time of the sale or transfer and the denominator of which is the combined number of Ordinary Shares (on an as-converted basis) at the time
owned by all Non-Selling Shareholders who elect to exercise their co-sale rights (if any Non-Selling Shareholder does not elect
to exercise the co-sale right to the full extent then its Ordinary Shares (on as-converted basis) for calculation in the denominator shall be proportionately reduced)
and the Selling Shareholder (“Co-Sale Pro Rata Portion”). 
 (b) Transferred
Shares. Each participating Non-Selling Shareholder shall effect its participation in the sale by promptly delivering to the Selling Shareholder for transfer to the prospective purchaser one or more
certificates, in addition to a duly executed instrument of transfer which represent: 
 (i) the number of Ordinary Shares which such Non-Selling Shareholder elects to sell; 

  
 21 

 (ii) that number of Preferred Shares which is at such time convertible into the number of
Ordinary Shares that such Non-Selling Shareholder elects to sell; provided in such case that, if the prospective purchaser objects to the delivery of Preferred Shares in lieu of Ordinary Shares, such Non-Selling Shareholder shall convert such Preferred Shares into Ordinary Shares and deliver Ordinary Shares as provided in subsection 4.3(b)(i) above. The Company agrees to make any such conversion
concurrent with the actual transfer of such shares to the purchaser; or 
 (iii) a combination of the above. 

(c) Payment to Preferred Shareholder. The share certificate or certificates that the participating
Non-Selling Shareholder delivers to the Selling Shareholder pursuant to Section 4.3(b) shall be surrendered to the Company for cancellation and the register of members of the Company
shall be updated in consummation of the sale of the Offered Shares pursuant to the terms and conditions specified in the Transfer Notice, and the Selling Shareholder shall concurrently therewith remit to such
Non-Selling Shareholder that portion of the sale proceeds to which such Non-Selling Shareholder is entitled by reason of its participation in such sale. To the extent
that any prospective purchaser or purchasers prohibits such assignment or otherwise refuses to purchase any shares or other securities from a Non-Selling Shareholder exercising its co-sale right hereunder, the Selling Shareholder shall not sell to such prospective purchaser or purchasers any Ordinary Shares unless and until, simultaneously with such sale, the Selling Shareholder shall purchase
such shares or other securities from such Non-Selling Shareholder. 
 (d) Right to Transfer.
To the extent the Non-Selling Shareholders do not elect to participate in the sale of the Offered Shares subject to the Transfer Notice, the Selling Shareholder may, not later than ninety (90) Business
Days following delivery to the Company and each of the Non-Selling Shareholders of the Transfer Notice, conclude a transfer of the remaining Offered Shares covered by the Transfer Notice and not elected to be
purchased by the Company and/or the Non-Selling Shareholders, which in each case shall be on substantially the same terms and conditions as those described in the Transfer Notice. In the event the Selling
Shareholder does not consummate the sale of such Offered Shares within ninety (90) Business Days in accordance with this Section 4.3(d), the rights of the Company and the
Non-Selling Shareholders under Sections 4.2 and 4.3 shall be re-invoked and shall be applicable to each subsequent disposition of such Offered Shares by
the Selling Shareholder until such rights lapse in accordance with the terms of this Agreement. The Selling Shareholders shall cause any prospective purchaser of such shares to comply with this Agreement and Restated Articles, as maybe amended from
time to time. Any proposed transfer on terms and conditions which are materially different from those described in the Transfer Notice, as well as any subsequent proposed transfer of any Ordinary Shares by the Selling Shareholder, shall again be
subject to the right of first refusal of the Company and the Non-Selling Shareholders and the co-sale right of the Non-Selling
Shareholder and shall require compliance by the Selling Shareholder with the procedures described in Sections 4.2 and 4.3 of this Agreement. 

4.4 Permitted Transfers. Notwithstanding anything to the contrary contained herein, the right of first refusal and co-sale rights of the Company and/or the Preferred Shareholder as set forth in Section 4.2 and Section 4.3 above and the transfer restrictions set forth in
Section 4.5 below shall not apply to (a) any sale or Transfer of Ordinary Shares to the Company pursuant to a repurchase right or right of first refusal held by the Company in the event of a termination (either
voluntary or involuntary) of employment or consulting relationship; and (b) any Transfer by an Ordinary Shareholder of Ordinary Shares held by such 

  
 22 

 
Ordinary Shareholder as of the date hereof to its Controlled Affiliates, provided that the transferring Ordinary Shareholder continues to exercise effective control over said Ordinary
Shares including voting rights (each transferee pursuant to the foregoing subsections (a) or (b), a “Permitted Transferee”); provided that adequate documentation therefor is provided to the Preferred Shareholders to
their satisfaction and that any such Permitted Transferee agrees in writing to be bound by this Agreement in place of the relevant transferor; provided, further, that such transferor shall remain liable for any breach by such Permitted
Transferee of any provision hereunder. 
 4.5 Prohibited Transfers. 

(a) Until the Qualified Initial Public Offering, none of the Ordinary Shareholders shall, without the prior written approval of the Majority
Preferred Shareholders, directly or indirectly Transfer through one or a series of transactions any Ordinary Shares held by it to any person. 

(b) No Shareholder may directly or indirectly Transfer any Shares to any Competitor. 

(c) Any attempt by a Party to sell or transfer any share of the Company in violation of this Section 4 shall be void
and the Company hereby agrees it will not effect such a transfer nor will it treat any alleged transferee as the holder of such shares without the requisite written consent. 

4.6 Restriction on Indirect Transfers. The Parties agree that the transfer restrictions set out in this
Section 4 shall not be circumvented or otherwise avoided by the holding of any Equity Securities of the Company indirectly through a company or other entity that can itself be sold in order to dispose of an interest in the
Equity Securities of the Company free of such restrictions. Any transaction or Transfer directly or indirectly of shares of a shareholder of the Company or of any company (or other entity) having Control (as defined in
Section 12.6 below) over such shareholder of the Company shall be treated as a transfer of the Equity Securities of the Company held by that Shareholder, and the provisions of this Agreement that apply in respect of the
transfer of Equity Securities of the Company shall apply to such transfer. 
 4.7 Legend. 

(a) Each certificate representing the Ordinary Shares shall be endorsed with the following legend: 

“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OF THE UNITED STATES, AS AMENDED.
THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER SET FORTH IN A SHAREHOLDERS AGREEMENT, AS AMENDED AND RESTATED FROM TIME TO TIME, A COPY OF WHICH MAY BE
OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY.” 

  
 23 

 (b) Each Party agrees that the Company may instruct its transfer agent to impose transfer
restrictions on the shares represented by certificates bearing the legend referred to in Section 4.7(a) above to enforce the provisions of this Agreement and the Company agrees to promptly do so. The legend shall be removed
upon termination of the provisions of this Section 4. 
 4.8 Termination. The provisions under this
Section 4 shall terminate upon the earliest to occur of (i) the consummation of the Qualified Initial Public Offering, (ii) the consummation of an IPO in a Recognized Exchange duly approved by the Board where all
Preferred Shares are converted into Ordinary Shares, or where such provisions are required to be terminated by applicable laws or stock exchange requirements; or (iii) the closing of a Deemed Liquidation Event. 

5. ASSIGNMENT AND AMENDMENT. 
 5.1
Assignment and Amendment. Notwithstanding anything herein to the contrary: 
 (a) Information Rights; Registration
Rights. The Information Rights and Inspection Rights under Section 1.1 may be assigned to any Rights Holder, and the registration rights of the Holders under Section 2 may be assigned to any
Holder or to any person acquiring Registrable Securities, in each case, in accordance with the terms of this Agreement; provided, however, that in either case no Party may be assigned any of the foregoing rights unless the Company is
given written notice by the assigning Party, stating the name and address of the assignee and identifying the securities of the Company as to which the rights in question are being assigned; provided further, that any such assignee
shall receive such assigned rights subject to all the terms and conditions of this Agreement, including without limitation the provisions of this Section 5. 

(b) Right of Participation; Right of First Refusal; Co-Sale Right. The rights of each holder of
Preferred Shares under Section 3 and each holder of Preferred Shares under Section 4 are fully assignable in connection with a transfer of shares of the Company by such holder of Preferred Shares
in accordance with the terms of this Agreement; provided, however, that no Party may be assigned any of the foregoing rights unless the Company is given written notice by the holder of the Preferred Shares, stating the name and address
of the assignee and identifying the securities of the Company as to which the rights in question are being assigned; and provided further, that any such assignee shall receive such assigned rights subject to all the terms and
conditions of this Agreement. 
 5.2 Amendment of Rights. Any provision in this Agreement may be amended and the observance thereof
may be waived (either generally or in a particular instance and either retroactively or prospectively), only by the written consent of the Company and the persons or entities holding (a) at least [***] percent ([***]%) of the Series A Preferred
Shares then outstanding and (b) at least [***] percent ([***]%) of the Series B Preferred Shares then outstanding; provided, however, that (i) no provision hereof may be amended or waived, in each case, in any way which would
adversely affect the rights of any holder of Preferred Shares hereunder in a manner disproportionate to any adverse effect such amendment or waiver would have on such other holder without the consent of such disproportionately affected holder, and
(ii) any holder of Preferred Shares may waive any of its rights hereunder without obtaining the consent of any other holders of Preferred Shares or their assigns; provided, further, however, that (1) Sections
1.1(a), 1.2(a), 1.3(b), 1.4, 7.1(A)(m) and 9.6 of this Agreement and this proviso (1) shall not be amended or waived without the express written consent of Ascendis, (2) Sections 1.1(a),
1.2(b), 1.3(a), 7.1(A)(m) and 9.6 of this Agreement and this proviso (2) shall not be amended or waived without the express written consent of Vivo Capital, (3) 

  
 24 

 
Sections 1.1(a), 1.2(d), 7.2(B) and 9.6 of this Agreement and this proviso (3) shall not be amended or waived without the express written consent of Sequoia,
(4) Section 1.3(c) of this Agreement and this proviso (4) shall not be amended or waived without the express written consent of Sofinnova, and (5) Section 1.3(d) of this Agreement
and this proviso (5) shall not be amended or waived without the express written consent of Sherpa. Any amendment or waiver effected in accordance with this Section 5.2 shall be binding upon each Party and their
respective assigns. The Company shall give prompt written notice of any amendment, termination, or waiver hereunder to any Party that did not consent in writing thereto. 

6. CONFIDENTIALITY AND NON-DISCLOSURE. 

6.1 Investor’s Confidentiality Obligation. Each Investor agrees that such Investor will, and will cause its
Affiliates and Representatives to, keep confidential and will not disclose, divulge, or use for any purpose (other than for its investment in the Company) the terms of this Agreement and any confidential information obtained from the Group Companies
(including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Subsection by
such Investor), (b) is or has been independently developed or conceived by such Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to such Investor by a third party without a
breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its Affiliates, attorneys, accountants, consultants, and other
professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees
to be bound by the provisions of this Subsection; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that
such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, regulation, rule, court order or subpoena
(including the rules and regulations of the U.S. Securities and Exchange Commission and the rules of any stock exchange), provided that such Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the
extent of any such required disclosure. For purposes of this Agreement, “Affiliate” shall mean, with respect to a Person, any other Person that, directly or indirectly, Controls, is Controlled by or is under common Control with such
Person. In the case of an Investor other than Sequoia, the term “Affiliate” also includes (w) any direct or indirect shareholder of such Person, (x) any of such Person’s general partners or limited partners, (y) the
fund manager managing such Person (and general partners, limited partners and officers thereof) and other funds managed by such fund manager, (z) trusts Controlled by or for the benefit of any such Person referred to in (w), (x) or (y), and
(z) any fund or holding company formed for investment purposes that is promoted, sponsored, managed, advised or serviced by Persons or any of their Affiliates. Notwithstanding the foregoing, the Parties acknowledge and agree that (A) the
name “Sequoia” is commonly used to describe a variety of entities (collectively, the “Sequoia Entities”) that are affiliated by ownership or operational relationship and engaged in a broad range of activities related to
investing and securities trading and (B) notwithstanding any other provision of this Agreement to the contrary, this Agreement shall not be binding on, or restrict the activities of, any (1) Sequoia Entity outside of the Sequoia China
Sector Group , (2) entity primarily engaged in investment and trading in the secondary securities market; (3) the ultimate beneficial owner of a Sequoia Entity (or its general partner or ultimate general partner) who is a natural Person, and
such Person’s relatives (including but 

  
 25 

 
without limitation, such Person’s spouse, parents, children, siblings, mother-in-law and father-in-law and brothers and sisters-in-law), (4) any officer, director or employee of a
Sequoia Entity (or its general partner or ultimate general partner) and such Person’s relatives, and (5) for the avoidance of doubt, any portfolio companies of any Sequoia Entity and portfolio companies of any affiliated investment fund or
investment vehicle of any Sequoia Entity. For purposes of the foregoing, the “Sequoia China Sector Group” means all Sequoia Entities (whether currently existing or formed in the future) that are principally focused on companies
located in, or with connections to, the People’s Republic of China that are exclusively managed by Sequoia. For the avoidance of doubt, any breach of the confidentiality and non-use obligations by any of
its Affiliates or Representative shall be deemed a breach by such Investor, for which such Investor shall be fully responsible. 
 6.2
Press Releases, Etc. No announcement regarding any of the confidential information covered in Section 6.1 above in a press release, conference, advertisement, announcement, professional or trade publication, mass
marketing materials or otherwise to the general public may be made without the prior written consent of Ascendis, Vivo and Sequoia (which consent shall not be unreasonably withheld), except as may otherwise be required by law, regulation, rule,
court order or subpoena (including the rules and regulations of the U.S. Securities and Exchange Commission and the rules and regulations of any stock exchange). 

6.3 Other Information. The provisions of this Section 6 shall be in addition to, and not in substitution for,
the provisions of any separate nondisclosure agreement executed by any of the Parties with respect to the transactions contemplated hereby. 

6.4 Notices. All notices required under this section shall be made pursuant to Section 12.1 of this Agreement.

 7. PROTECTIVE PROVISIONS. 
 7.1
Approval by Shareholders. 
 (A) In addition to and subject to such other limitations as may be provided in the Restated
Articles, so long as at least [***] Series A Preferred Shares (as adjusted for share dividends, subdivisions, consolidations, splits, combinations, recapitalizations or similar events) remain outstanding, none of the Group Companies shall directly
or indirectly, whether in a single transaction or series of related transactions, whether by amendment, merger, consolidation or otherwise, carry out any of the following actions except with the approval of holders of at least [***] percent ([***]%)
of the Series A Preferred Shares then outstanding, via written consent or affirmative vote at a meeting, as a separate class: 
 (a) any
repeal, amendment, modification or change of the memorandum or the articles or other similar constitutive documents of any Group Company in a manner that adversely affects the powers, preferences or rights of the Series A Preferred Shares; 

(b) any amendment, modification or change of any rights, preferences, privileges or powers of, or any restrictions provided for the benefit of,
the Series A Preferred Shares or any amendment, modification or change of any rights, powers or benefit attached to the Ordinary Shares, Non-voting Ordinary Shares or other classes or series of shares having
the effect of or may result in any rights, preferences, privileges or powers of the Series A Preferred Shares being prejudiced; 

  
 26 

 (c) liquidation, dissolution, winding up or reorganization of any Group Company, or any
Deemed Liquidation Event; 
 (d) any issue, allotment or grant of any options, warrants or similar rights conferring on any Person the right
to acquire, any shares, securities or equity interest in the Group Companies (except where such issue, allotment or grant is incidental to the exercise of conversion rights applicable to the Preferred Shares or pursuant to the ESOP Plan (as defined
below) or other pre-approved share option plans, share incentive scheme or other schemes and agreements of similar nature); 

(e) any action that authorizes, creates or issues shares of any class or series, or other securities of whatever description, or reclassifies
or converts any issued or outstanding shares of the Company into shares, having rights, priority or preferences superior to or on a parity with the Series A Preferred Shares, whether in terms of voting rights, dividends or amounts payable in the
event of any voluntary or involuntary liquidation or distribution of the Company or otherwise; 
 (f) any increase or decrease in the number
of authorized Series A Preferred Shares, Ordinary Shares, or issuance of any Ordinary Shares except for issuance under the ESOP Plan (as defined below) or conversion of Preferred Shares; 

(g) any repurchase or redemption of any shares or other securities of the Company other than repurchases of shares from former employees,
officers, directors, consultants or other persons who performed services for the Company or any Group Company in connection with the cessation of such employment or service pursuant to the ESOP Plan (as defined below); 

(h) the declaration or payment of a dividend on any share or other securities of any Group Company and any change of dividend policy of any
Group Company; 
 (i) any action that creates, or authorizes the creation of, any debt security; 

(j) changing the principal business of the Group Companies, entering into any new line of business, or exiting the current line of business;

 (k) the creation, adoption and material amendment of any equity incentive plan or equivalent by the Group Companies (including total
number of shares reserved under such plan); 
 (l) any increase or decrease in the authorized number of members of the board of directors of
any Group Company, or change the manner in which the directors are appointed; and 
 (m) any agreement or commitment by any Group Company to
do any of the foregoing. 
 Notwithstanding anything to the contrary contained herein, where any act listed in sub-clauses (a) through (m) above requires a resolution of the shareholders, and if the shareholders vote in favor of such act but the approval of the holders of at least [***] percent ([***]%) of the Series A
Preferred Shares then outstanding has not yet been obtained in accordance with this Section 7.1, the holders of Series A Preferred Shares that voted against such resolution shall have, in such vote at a meeting of the
shareholders, the voting rights equal to the aggregate voting power of all the shareholders of the Company who voted in favor of the resolution plus one (1). 

  
 27 

 (B) In addition to and subject to such other limitations as may be provided in the Restated
Articles, so long as at least [***] Series B Preferred Shares (as adjusted for share dividends, subdivisions, consolidations, splits, combinations, recapitalizations or similar events) remain outstanding, none of the Group Companies shall directly
or indirectly, whether in a single transaction or series of related transactions, whether by amendment, merger, consolidation or otherwise, carry out any of the following actions except with the approval of holders of at least [***] percent ([***]%)
of the Series B Preferred Shares then outstanding, via written consent or affirmative vote at a meeting, as a separate class: 
 (a) any
repeal, amendment, modification or change of the memorandum or the articles or other similar constitutive documents of any Group Company in a manner that adversely affects the powers, preferences or rights of the Series B Preferred Shares; 

(b) any amendment, modification or change of any rights, preferences, privileges or powers of, or any restrictions provided for the benefit of,
the Series B Preferred Shares or any amendment, modification or change of any rights, powers or benefit attached to the Ordinary Shares, Non-voting Ordinary Shares or other classes or series of shares having
the effect of or may result in any rights, preferences, privileges or powers of the Series B Preferred Shares being prejudiced; 
 (c)
liquidation, dissolution, winding up or reorganization of any Group Company, or any Deemed Liquidation Event; 
 (d) any issue, allotment or
grant of any options, warrants or similar rights conferring on any Person the right to acquire, any shares, securities or equity interest in the Group Companies (except where such issue, allotment or grant is incidental to the exercise of conversion
rights applicable to the Preferred Shares or pursuant to the ESOP Plan (as defined below) or other pre-approved share option plans, share incentive scheme or other schemes and agreements of similar nature);

 (e) any action that authorizes, creates or issues shares of any class or series, or other securities of whatever description, or
reclassifies or converts any issued or outstanding shares of the Company into shares, having rights, priority or preferences superior to or on a parity with the Series B Preferred Shares, whether in terms of voting rights, dividends or amounts
payable in the event of any voluntary or involuntary liquidation or distribution of the Company or otherwise; 
 (f) any increase or decrease
in the number of authorized Series B Preferred Shares, Ordinary Shares, or issuance of any Ordinary Shares except for issuance under the ESOP Plan (as defined below) or conversion of Preferred Shares; 

(g) any repurchase or redemption of any shares or other securities of the Company other than repurchases of shares from former employees,
officers, directors, consultants or other persons who performed services for the Company or any Group Company in connection with the cessation of such employment or service pursuant to the ESOP Plan (as defined below); 

  
 28 

 (h) the declaration or payment of a dividend on any share or other securities of any Group
Company and any change of dividend policy of any Group Company; 
 (i) any action that creates, or authorizes the creation of, any debt
security; 
 (j) changing the principal business of the Group Companies, entering into any new line of business, or exiting the current line
of business; 
 (k) the creation, adoption and material amendment of any equity incentive plan or equivalent by the Group Companies
(including total number of shares reserved under such plan); 
 (l) any increase or decrease in the authorized number of members of the board
of directors of any Group Company, or change the manner in which the directors are appointed; and 
 (m) any agreement or commitment by any
Group Company to do any of the foregoing. 
 Notwithstanding anything to the contrary contained herein, where any act listed in sub-clauses (a) through (m) above requires a resolution of the shareholders, and if the shareholders vote in favor of such act but the approval of the holders of at least [***] percent ([***]%) of the Series B
Preferred Shares then outstanding has not yet been obtained in accordance with this Section 7.1, the holders of Series B Preferred Shares that voted against such resolution shall have, in such vote at a meeting of the
shareholders, the voting rights equal to the aggregate voting power of all the shareholders of the Company who voted in favor of the resolution plus one (1). 

7.2 Approval by Board of Directors. 

(A) In addition to such other limitations as may be provided in the Restated Articles and subject to Section 1.2
hereof, none of the Group Companies shall, directly or indirectly, whether in a single transaction or series of related transactions, whether by amendment, merger, consolidation or otherwise, except with the approval of a majority of the Series A
Directors, via written consent or affirmative vote at a meeting: 
 (a) make any loan or advance to, or own any share or other securities of,
any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by a Group Company; 
 (b) make any loan or
advance to any person, including, any employee or director of any Group Company, except advances and similar expenditures in the ordinary course of business or under the terms of an equity incentive plan approved by the Board; 

(c) guarantee any indebtedness except for trade accounts of the Group Companies or any Subsidiary arising in the ordinary course of business;

 (d) make any investment inconsistent with any investment policy approved by the Board; 

  
 29 

 (e) incur any aggregate indebtedness in excess of US$1,000,000 that is not already included
in a Board-approved budget, other than trade credit incurred in the ordinary course of business; 
 (f) enter into or be a party to any
transaction with any director, officer or employee of the Group Companies or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such person, or with any Shareholder
or its Affiliates or any director, officer or employee of such Shareholder or its Affiliates or any “associate” of any such person, other than transactions made in the ordinary course of business and pursuant to reasonable requirements of
the Group Companies’ business and upon fair and reasonable terms that are approved by a majority of the Board; 
 (g) hire, fire, or
change the compensation of the executive officers, and approve any and all option grants to the executive officers of any Group Company; 

(h) sell, assign, license, sublicense, pledge or encumber material technology or intellectual property of any Group Company; 

(i) enter into any corporate strategic relationship involving the payment, contribution or assignment by any Group Company or to any Group
Company of assets greater than US$500,000; 
 (j) enter into or be a party to any other transaction involving the payment, contribution or
assignment by any Group Company or to any Group Company of assets greater than US$10,000,000, or any exclusive commercial relationship, in each case, other than in the ordinary course of business; or 

(k) any agreement or commitment by any Group Company to do any of the foregoing. 

(B) In addition to such other limitations as may be provided in the Restated Articles and subject to Section 1.2
hereof, none of the Group Companies shall, directly or indirectly, whether in a single transaction or series of related transactions, whether by amendment, merger, consolidation or otherwise, except with the approval of the Series B Director, via
written consent or affirmative vote at a meeting, for so long as Sequoia is entitled to appoint the Series B Director: 
 (a) make any loan
or advance to any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by a Group Company; 
 (b) make any
loan or advance to any person, including, any employee or director of any Group Company, except advances and similar expenditures in the ordinary course of business or under the terms of an equity incentive plan approved by the Board; 

(c) incur any aggregate indebtedness in excess of US$2,000,000 that is not already included in a Board-approved budget, other than trade credit
incurred in the ordinary course of business; 
 (d) guarantee any indebtedness in excess of US$2,000,000 except for trade accounts of the
Group Companies or any Subsidiary arising in the ordinary course of business; 

  
 30 

 (e) purchase or dispose of any business/assets of the Group Companies in excess of
US$2,000,000 in aggregate, either in a single transaction or a series of related transactions, other than in the ordinary course of business; 

(f) make equity investment in excess of US$5,000,000 in any subsidiary or other corporation, partnership, or other entity unless, immediately
prior to the consummation of such equity investment, it is wholly owned by a Group Company; 
 (g) enter into or be a party to any other
transaction involving the payment, contribution or assignment by any Group Company or to any Group Company of assets greater than US$10,000,000, or any exclusive commercial relationship, in each case, other than in the ordinary course of business;
or 
 (h) agree or commit to do any of the foregoing. 

7.3 Termination. The provisions set forth under this Section 7 shall terminate upon the earliest to occur of
(i) the consummation of the Qualified Initial Public Offering, (ii) the consummation of an IPO in a Recognized Exchange duly approved by the Board where all Preferred Shares are converted into Ordinary Shares, or where such provisions are
required to be terminated by applicable laws or stock exchange requirements; or (iii) the closing of a Deemed Liquidation Event. 
 8. DRAG
ALONG. 
 8.1 In the event that (i) the holders of at least [***] ([***]) of the outstanding Preferred Shares (voting together as a
single class and calculated on an as-converted basis) (the “Approving Shareholders”); and (ii) the Board of Directors approve in writing, to sell or transfer the shares or assets of any
Group Company in any transaction or a series of related transactions that would qualify as a Deemed Liquidation Event, to a bona fide third party, or a group of bona fide related parties, whereby the gross proceeds derived from such transaction(s)
shall be no less than US$[***] (the “Change of Control”), then the Company shall promptly notify each of the remaining shareholders of the Company (the “Remaining Shareholders”, including without limitation, each of
the holders of Ordinary Shares, Non-voting Ordinary Shares, Series A Preferred Shares and Series B Preferred Shares) in writing of such vote, consent and/or agreement and the material terms and conditions of
such Change of Control, whereupon each Remaining Shareholder shall, in accordance with instructions received from the Company (the “Drag Along Instructions”), vote all of its voting securities of the Company in favor of, otherwise
consent in writing to, and/or otherwise sell or transfer all or the pro rata portion (calculated on an as-converted basis) of their shares in such Change of Control (including without limitation tendering
original share certificates for transfer, signing and delivering share transfer certificates, share sale or exchange agreements, and certificates of indemnity relating to any shares in the share capital of the Company in the event that such
Remaining Shareholder has lost or misplaced the relevant share certificate) on the same terms and conditions as were agreed to by the Approving Shareholders. 

8.2 Notwithstanding the foregoing, a Remaining Shareholder will not be required to comply with Section 8.1 above in
connection with any proposed Change of Control, unless (i) the liability for indemnification, if any, of such Remaining Shareholder in the Change of Control and for the inaccuracy of any representations and warranties made by the Company and/or
its shareholders in connection with such Change of Control, is several and not joint with any other Person, and is proportionate to, and does not exceed, the amount of consideration 

  
 31 

 
paid to such Remaining Shareholder in connection with such Change of Control, (ii) if applicable, such Remaining Shareholder is not required to make representations and warranties on any
business and operational related matters, and (iii) such Remaining Shareholder is not required to agree (unless such Shareholder is a Company officer or employee) to any covenant not to compete or covenant not to solicit customers, employees or
suppliers of any party to such Change of Control. 
 8.3 In furtherance of the foregoing, the Company is hereby expressly authorized by each
Remaining Shareholder to take any or all of the following actions on such Remaining Shareholder’s behalf (without receipt of any further consent by such Remaining Shareholder), provided such Remaining Shareholder fails to take necessary actions
as required under the Drag Along Instructions, to: (i) vote all of the voting securities of such Remaining Shareholder in favor of any such Change of Control and cause the director(s) appointed by such Remaining Shareholder to vote in favor of
any such Change of Control; (ii) otherwise consent on such Remaining Shareholder’s behalf to such Change of Control; (iii) sell all or the pro rata portion (calculated on an as-converted basis)
of such Remaining Shareholder’s shares in such Change of Control, in accordance with the terms and conditions of this Section; and/or (iv) act as the Remaining Shareholder’s attorney in fact in relation to any such Change of Control
and have the full authority to sign and deliver, on behalf of such Remaining Shareholder, share transfer certificates, share sale or exchange agreements and certificates of indemnity relating to any shares in the share capital of the Company in the
event that such Remaining Shareholder has lost or misplaced the relevant share certificate. Notwithstanding anything to the contrary in this Agreement, none of the transfer restrictions set forth in this Agreement shall apply in connection with such
Change of Control. 
 8.4 Upon written notice to the Company from the Approving Shareholders, the Company shall initiate a process intended
to result in a Change of Control and shall cause its officers, employees, consultants, counsel and advisors to take all necessary and appropriate actions to facilitate a Change of Control. 

9. COVENANTS; UNDERTAKINGS 
 9.1
Controlled Foreign Corporation. Each year, based on and in reliance of the information provided by the shareholders of the Company (the “Shareholders”) within a reasonable time after being requested, the Company shall make
due inquiry with its tax advisors regarding whether the Company or any of its Subsidiaries is treated as a “Controlled Foreign Corporation” (“CFC”) as defined in the United States Internal Revenue Code of 1986 (the
“Code”), whether any portion of the Company’s or any of its Subsidiaries’ income is (a) “Subpart F Income” (as defined in Section 952 of the Code) (“Subpart F Income”) or (b) “global
intangible low-taxed income” (as defined in Section 951A(b) of the Code) (“GILTI”) and each Shareholder’s share, if any, of such Subpart F Income and/or GILTI (regardless of
whether a Shareholder is a “United States Shareholder” or not). Upon written request of any Investor who is a United States Shareholder (or whose direct or indirect owners are United States Shareholders) with respect to the Company or any
Group Company within the meaning of Section 951(b) of the Code, the Company will (i) use best efforts to provide in writing such information as is in its possession and reasonably available concerning its Shareholders and Affiliates to
assist such Investor in determining whether the Company or any Group Company is a CFC and (ii) provide such Investor with reasonable access to such information as is in the Company’s or Group Company’s possession and reasonably
available as may be required by such Investor (A) to determine the Company’s (or Group Company’s) status as a CFC, (B) to determine whether such Investor is required to report its pro rata portion of the Company’s (or

  
 32 

 
Group Company’s) “Subpart F income” (as defined in Section 952 of the Code) on its United States federal income tax return, or (C) to allow such Investor to
otherwise comply with applicable United States federal income tax laws (including with respect to the making of any determinations under Section 951A of the Code); provided that the Company may require such Investor to enter into a
confidentiality agreement in customary form. 
 9.2 Passive Foreign Investment Company.
The Company shall use commercially reasonable efforts to avoid being a “passive foreign investment company” within the meaning of Section 1297 of the Code (“PFIC”) for the current and any future taxable year.
The Company shall make due inquiry with its tax advisors on at least an annual basis regarding its status as a PFIC, and if the Company is informed by its tax advisors that it has become a PFIC, or that it is likely that the Company will be
classified as a PFIC for any taxable year, the Company shall promptly notify each Investor of such status or risk, as the case may be, in each case no later than forty-five (45) days following the end of the Company’s taxable
year. The Company shall provide its Investors with annual financial information in the form to the reasonable satisfaction of such Investor as soon as reasonably practicable following the end of each taxable year of such Investor (but in no
event later than forty-five (45) days following the end of each such taxable year), and shall, upon the request in writing by any Investor, provide such Investor with access to such other information, as is in the Company’s possession and
reasonably available, as may be required for purposes of filing U.S. federal income tax returns in connection with a qualified electing fund election or other tax filing in respect of the Company’s status of a PFIC. In the event that it is
determined by the Company’s or such Investor’s tax advisors that the control documents in place between one or more of the Company’s wholly owned Subsidiaries and/or the Company, on the one hand, and any of the Group Companies
organized in the PRC that is not a wholly foreign owned enterprise, on the other hand, do not allow the Company to look through the Group Companies to their assets and income for purposes of the PFIC rules and regulations under the Code, the
Company shall use its best efforts to take such actions as are reasonably necessary or advisable, including the amendment of such control documents, to qualify for such look-through treatment of the Group Companies under the PFIC rules and
regulations under the Code. 
 9.3 U.S. Federal Income Tax. The Company is currently classified as a corporation (and not as a
partnership) for U.S. federal income tax purposes and shall not take any action (including the making of any election) inconsistent with the Company’s or any of its Subsidiaries’ classification for U.S. federal income tax purposes as a
corporation without the prior written consent of the Majority Preferred Shareholders. 
 9.4 Subsidiary Covenants. The Company shall
at any time institute and shall keep in place arrangements satisfactory to the Board such that the Company (i) will control the operations of any Group Company and (ii) will be permitted to properly consolidate the financial results for
such entity in consolidated financial statements for the Company prepared under the PRC GAAP and IFRS. The Company shall, and shall cause each Group Company and use its reasonably best efforts to cause such Group Company’s respective directors,
officers, employees, agents and other persons acting on its behalf or purporting to act on its behalf to, comply with the US Foreign Corrupt Practices Act, as amended, in all material respects. 

9.5 Additional Covenants. The Company shall take all necessary actions to maintain its Subsidiaries, as is necessary to conduct the
Company’s business as conducted or as proposed to be conducted. The Company shall, and shall use its best efforts to cause each Group Company to, comply in all material respects with all applicable Laws, rules, and regulations on a continuing
basis. All material aspects of such formation, maintenance and compliance of each Group Company shall be subject to the review, approval and oversight by the Board. 

  
 33 

 9.6 Non-Compete. Ascendis undertakes and
covenants to the Company that commencing from the date of this Agreement, it will not, without the prior written consent of the Company, either on its own account or through any of his/its Controlled Affiliates, or in conjunction with or on behalf
of any other person: (i) carry out or be engaged in the research, development, manufacture or commercialization of [***] in the People’s Republic of China (including Hong Kong, Macao and Taiwan) (the “Competing Business”);
(ii) directly or indirectly own any interest in a third party engaged in the Competing Business other than holding in aggregate less than [***] percent ([***]%) of the issued share capital of any entity engaged in the Competing Business as a passive
investor; (iii) solicit or entice away or attempt to solicit or entice away from any Group Company, any person, firm, company or organization who is a customer, client, employee, representative, agent or correspondent of such Group Company or
in the habit of dealing with such Group Company, or (iv) provide services to any entity engaged in the Competing Business [***]. For clarity; subsection (iv) shall not apply to services that Ascendis provides to a competing company outside
the Territory (as defined in the Rights Agreements) for the use outside of the Territory. For avoidance of the doubt, all activities performed pursuant to the following agreements shall not constitute engagement in the Competing Business and neither
Ascendis nor its Controlled Affiliates shall be deemed to have engaged in any Competing Business as a result of any activities performed under such agreements: (a) [***] and (b) [***]. In the event that any entity, in which Ascendis owns directly or
indirectly [***] percent ([***]%) or more of the issued share capital and/or Ascendis is not merely a passive investor, becomes [***] in the Competing Business, Ascendis shall decrease its holding in such entity to less than [***] percent ([***]%)
immediately and in any event within [***] ([***]) months after the time when Ascendis comes to own directly or indirectly [***] percent ([***]%) or more of the issued share capital of such entity engaged in the Competing Business [***]. The
provisions of this Section 9.6 shall terminate upon the earlier to occur of (i) the closing of a Deemed Liquidation Event; or (ii) the termination of each of the three Exclusive License Agreements, dated
November 7, 2018, by and among the Company and each of Ascendis Pharma Growth Disorders A/S, Ascendis Pharma Endocrinology Division A/S and Ascendis Pharma Bone Diseases A/S (the “Rights Agreements”). For clarity, nothing in
this Section 9.6 shall restrict or limit the ability of Ascendis or its Affiliates to fulfill or perform its obligations under any other agreement with the Company, including without limitation any Rights Agreement or any
clinical or commercial supply agreement entered into by Ascendis or its Affiliates with the Company. [***]. 
 9.7 Management.
Mr. Pony Lu and Dr. Dandan DONG have been nominated to serve as the Chief Executive Officer and Chief Business Officer of the Company, which nominations have been duly approved by the Board. The Company shall reasonably compensate for the
services provided by Dr. Dandan DONG to the Group Companies. 
 9.8 ESOP. The Company shall cause each of the grantees under the
employee equity incentive plan of the Company (the “ESOP Plan”) to enter into such grant documents which shall provide the Company with a right of first refusal on grantee’s transfer of shares and shall further provide that if
the Company fails to exercise its right of first refusal, each of the Investors shall have a right of first refusal with respect to the shares not purchased by the Company pursuant to Section 4.2 above, in accordance with
its pro rata ownership of the Company (on an as-converted basis), and if any Investor elects not to exercise its right of first 

  
 34 

 
refusal with respect to such shares, it shall have the right to sell its pro rata shares together with the transferring grantee pursuant to Section 4.3 above. In
addition, the Company shall ensure that each holder of the Non-voting Ordinary Shares representing no less than one percent (1%) of the Company’s total outstanding Ordinary Shares on fully-diluted and as-converted basis shall execute a joinder agreeing to the terms of this Agreement. 
 9.9 D&O
Insurance. The Company will purchase D&O insurance with a carrier and in an amount satisfactory to the Board within sixty (60) days of the Closing. In the event any Group Company merges with another entity and is not the surviving
corporation, or transfers all of its assets, proper provisions shall be made so that successors of such Group Company assume such Group Company’s obligations with respect to indemnification of Directors. Upon request by the Majority Preferred
Shareholders or Ascendis, the other Group Companies will purchase D&O insurance with a carrier and in an amount satisfactory to the board of directors of the relevant Group Company. 

9.10 Maintaining and Obtaining Licenses and Permits for the Principal Business. As soon as practicable after the Closing, each of the
Group Companies shall (a) obtain in a timely manner and maintain all requisite Consents and Permits for conducting its principal business in compliance with all material aspects with applicable Laws, and (b) if so required by any
applicable Laws, obtain additional Consents and Permits necessary for conducting its principal business as soon as possible but in any event no later than the time limit required by the applicable Laws or the competent Governmental Authorities,
including but not limited to completing the filing with human genetic resources authority of the PRC before transmission of or permitting any Person to transmit to Ascendis (or any Affiliate of Ascendis) any human genetic resources data derived from
the phase III clinical trials of TransCon hGH conducted by the Group Companies in the Territory. 
 9.11 Employment Agreement and
Confidentiality, Non-Competition and Intellectual Property Rights Agreements. The Group Companies shall cause each of their respective current and future employees to enter into an employment agreement
using such form that is satisfactory to the Majority Preferred Shareholders. The Group Companies shall cause each of their respective current and future employees and consultants to enter into a confidentiality,
non-competition, non-solicitation and proprietary information and inventions assignment agreement using such form that is satisfactory to the Majority Preferred
Shareholders. 
 9.12 Non-solicitation. The Group Companies shall not, and shall not permit
any of its Subsidiaries or Affiliates or any of its or their respective directors, officers, managers, or employees to, directly or indirectly, solicit for employment or engagement, or employ or in any other way interfere with the employment
relationship of any director, officer, senior member of management or any employee of: i) Ascendis or any of Ascendis’ subsidiaries or Affiliates within the period that Ascendis or any of its Affiliates own, directly or indirectly, any of the
shares of any Group Company and two years thereafter, except for any general solicitation that does not specifically target at the foregoing personnel, or ii) Sequoia or any of Sequoia’s subsidiaries or Affiliates within the period that Sequoia
or any of its Affiliates own, directly or indirectly, any of the shares of any Group Company and two years thereafter, except for any general solicitation that does not specifically target at the foregoing personnel. 

9.13 Use of Name and Press. Without the written consent of any Investor, the Group Companies and any other Investors (excluding such
Investor), shall not use the name or brand of such Investor or its Affiliate except to the extent such use is required pursuant to applicable laws or rules of stock exchange or is in the application materials for the IPO), claim itself as a partner
of such Investor or its Affiliate, make any similar representations. 

  
 35 

 9.14 Compliance & Anti-Corruption. Upholding ethical
standards, acting with integrity and in compliance with applicable laws and regulations, is essential to the Group Companies. Each of the Group Companies undertakes to conduct its business in accordance with all applicable laws and regulations. The
Company shall not (and shall not permit any of its Subsidiaries or Affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment
to, or otherwise contribute any item of value, directly or indirectly, to any third party, including any Non-U.S. Official (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended
(the “FCPA”)), in each case, in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company shall (and shall cause each of its Subsidiaries and Affiliates to) cease all of
its or their respective activities, as well as remediate any actions taken by the Company, its Subsidiaries or Affiliates, or any of their respective directors, officers, managers, employees, contractors, representatives or agents in violation of
the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company shall (and shall cause each of its Subsidiaries and Affiliates to) maintain processes and procedures designed to prevent any person working for
or engaged by the Company and its Subsidiaries and Affiliates or any other third party in any way connected to the Company, from engaging in any activity, practice or conduct which would infringe any anti-bribery and anti-corruption laws,
regulations and codes, including but not limited to the UK Bribery Act and the FCPA. Furthermore, the Company shall (and shall cause each of its Subsidiaries and Affiliates to) maintain systems of internal controls (including, but not limited to,
accounting systems, purchasing systems and billing systems) to ensure compliance with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. Upon request, the Company agrees to provide responsive
information, documentation and/or certifications concerning its (and each of its Subsidiaries and Controlled Affiliates) compliance with applicable anti-corruption laws. The Company shall promptly notify each Investor in writing if the Company
suspects or becomes aware of any actual or potential fraud, non-compliance, misconduct or enforcement action, and promptly take all appropriate steps to resolve and correct any identified non-conformity. The Company undertakes to maintain adequate and accurate books and records to ensure compliance, including but not limited to using practices and normal systems and methodologies according to
IFRS. The Company shall, and shall cause any direct or indirect Subsidiary or entity Controlled by it, whether now in existence or formed in the future, to comply with the FCPA and any other applicable anti-corruption law. The Company shall use
its best efforts to cause any direct or indirect Subsidiary, whether now in existence or formed in the future, to comply in all material respects with all applicable laws. The Company hereby undertakes to adopt and implement anticorruption policy
within ninety (90) days following the date hereof and export control policy within 360 days following the date hereof, in each case, mutually acceptable to the Company and Sequoia. 

10. Termination and Consequences of Termination. 

10.1 Termination. This Agreement (i) may be terminated at any time by written agreement among the holders of (a) at least
[***] percent ([***]%) of the outstanding Series A Preferred Shares and (b) at least [***] percent ([***]%) of the outstanding Series B Preferred Shares; and (ii) shall be automatically terminated upon the dissolution of the Company 

  
 36 

 10.2 Effect of Termination. Upon the termination of this Agreement pursuant to
Section 10.1 above, the Company shall be dissolved and liquidated in accordance with the Restated Articles, the relevant Cayman Island Laws. The shareholders shall take any and all lawful actions, including without
limitation exercising their respective voting rights and causing their directors to exercise their voting rights in the Board, to ensure the approval of the dissolution of the Company. Notwithstanding anything to the contrary, the provisions of
Sections 6, 10, 11 and 12 shall survive the expiration or early termination of this Agreement and the termination, dissolution or liquidation of the Company. 

11. INDEMNIFICATION. 
 11.1 General
Indemnity. 
 (a) If a Party fails to perform any of its obligations under this Agreement (the “Breaching Party”), then,
following written notice by any other Parties hereto that has incurred Losses (as defined below) as a result of such failure (the “Non-Breaching Party”) and a ten (10) day opportunity to
cure such breach (should it be capable of cure), the Breaching Party shall indemnify such Non-Breaching Party for, all claims, losses, damages, liabilities, documented costs and expenses (including reasonable
attorneys’ fees) (the “Losses”) which have been incurred by such Non-Breaching Party as a result of a breach by a Breaching Party of any of its representations and warranties, covenants,
undertakings, or other obligations under this Agreement. 
 (a) NO PARTY SHALL BE LIABLE TO OTHER PARTIES, ITS RELATED PARTIES, THEIR
RESPECTIVE OFFICERS, DIRECTORS, AGENTS, REPRESENTATIVES OR EMPLOYEES WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT (OTHER THAN BREACH OF THE CONFIDENTIALITY OR NON-COMPETITION OBLIGATIONS HEREUNDER)
UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR ANY INCIDENTAL, CONSEQUENTIAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES OR LOST PROFITS. ABSENT ANY FRAUD, THE MAXIMUM INDEMNIFICATION LIABILITY OF ANY INVESTOR
THAT IS A BREACHING PARTY UNDER THIS SECTION 11 SHALL BE LIMITED TO THE VALUE OF THE SHARES OF THE COMPANY HELD BY SUCH INVESTOR. 
 11.2
Claim Notice Procedure. 
 Without limiting any other rights of the Non-Breaching Party in any
way (including their rights to pursue damages in respect of a claim for breach of any covenant or other obligation), any Non-Breaching Party shall have the right to make a claim for indemnity under this
Agreement promptly at any time after the date hereof and before the expiration of the applicable statute of limitation, by issuing a written claim notice (the “Claim Notice”) to the Breaching Party. The Claim Notice shall describe
the breach in question along with the Party’s determination of the following: 
 (a) the amount which would be necessary to put the
Company and/or the Non-Breaching Party, as the case may be, into the financial position which would have existed had there been no breach of any representations and warranties, covenants, undertakings, or
other obligations in question; and 

  
 37 

 (b) all costs suffered or incurred by the
Non-Breaching Party directly or indirectly, as a result of or in connection with such breach of representations and warranties, covenants, undertakings, or other obligations. 

11.3 Payment under Claim Notice. 

Within fifteen (15) Business Days after receipt of a Claim Notice, unless disputed in good faith in writing, the Breaching Party shall pay
to the Company and/or the Non-Breaching Party all of the amounts specified in the Claim Notice. 

11.4 No Deduction. 
 All
sums payable by the Breaching Party to the Company or the Non-Breaching Party under Section 11 shall be paid free and clear of all deductions or withholdings whatsoever save only as
may be required by law. If any such deductions or withholdings are required by law, the Breaching Party shall be obliged to pay to the relevant person such sum as will, after deduction or withholding has been made, leave that person with the
same amount as it would have been entitled to receive in the absence of any requirement to make a deduction or withholding. 
 11.5
Exclusive Remedy. 
 Except in the event of fraud and for equitable remedies, from and after the date hereof, the rights to
indemnification under this Section 11 shall be the sole and exclusive monetary remedy of the Non-Breaching Parties with respect to any breach of this Agreement. 

11.6 Director Indemnification. 

To the fullest extent permitted by applicable Laws, as such may be amended from time to time, the Company shall indemnify and hold harmless any
Director for any damage, demand, claim, liability, obligation, loss, cost, expense (including, without limitation, the fees and disbursements of attorneys, accountants, and consultants), deficiency, interest, penalty, impositions, assessments or
fines of any kind or nature, whether known or unknown, fixed or contingent, arising out of or resulting from such Director’s service to and activities on behalf of the Company. 

12. GENERAL PROVISIONS. 
 12.1
Notices. Except as may be otherwise provided herein, all notices, requests, waivers and other communications made pursuant to this Agreement shall be in writing and shall be conclusively deemed to have been duly given (a) when hand
delivered to the other Party, upon delivery; (b) when sent by facsimile at the number set forth in Exhibit A hereto, upon receipt of confirmation of error-free transmission; (c) seven (7) Business Days after deposit in the mail as
air mail or certified mail, receipt requested, postage prepaid and addressed to the other Party as set forth in Exhibit A; (d) four (4) Business Days after deposit with an international overnight delivery service, postage prepaid,
addressed to the Parties as set forth in Exhibit A with next-business day delivery guaranteed, provided that the sending Party receives a confirmation of delivery from the delivery service provider; or (e) when sent by email at the email
address set forth in Exhibit A hereto, upon receipt of confirmation of receipt. Each person making a communication hereunder by facsimile shall promptly confirm by telephone to the person to whom such communication was addressed each
communication made by it by facsimile pursuant hereto but the absence of such confirmation shall not affect the validity of any such communication. A Party may change or supplement the addresses given above, or designate additional addresses, for
purposes of this Section 12.1 by giving the other Party written notice of the new address in the manner set forth above. 

  
 38 

 12.2 Entire Agreement. This Agreement and the Share Purchase Agreement, any other
Transaction Documents, together with all the exhibits hereto and thereto, constitute and contain the entire agreement and understanding of the Parties with respect to the subject matter hereof and supersedes any and all prior negotiations,
correspondence, agreements, understandings, duties or obligations between the Parties respecting the subject matter hereof. Capitalized terms which are not defined hereinto shall have the same meaning as such in the Share Purchase Agreement. 

12.3 Governing Law. This Agreement shall be governed by and construed exclusively in accordance with the laws of the Hong Kong Special
Administrative Region without regard to principles of conflicts of law thereunder. 
 12.4 Severability. If any provision of this
Agreement is found to be invalid or unenforceable, then such provision shall be construed, to the extent feasible, so as to render the provision enforceable and to provide for the consummation of the transactions contemplated hereby on substantially
the same terms as originally set forth herein, and if no feasible interpretation would save such provision, it shall be severed from the remainder of this Agreement, which shall remain in full force and effect unless the severed provision is
essential to the rights or benefits intended by the Parties. In such event, the Parties shall use best efforts to negotiate, in good faith, a substitute, valid and enforceable provision or agreement which most nearly effects the Parties’ intent
in entering into this Agreement. 
 12.5 Third Parties. Nothing in this Agreement, express or implied, is intended to confer upon any
person, other than the Parties hereto and their permitted successors and assigns any rights or remedies under or by reason of this Agreement. 

12.6 Successors and Assigns. Subject to the provisions of Section 5.1, the provisions of this Agreement shall
inure to the benefit of, and shall be binding upon, the successors, permitted assigns, heirs, executors and administrators of the Parties hereto whose rights or obligations hereunder are affected by such provisions. Notwithstanding anything contrary
in this Agreement, this Agreement and the rights and obligations herein may be assigned or transferred by any Investors to any of its Affiliates that are not Competitors; provided that in each case the transferee will agree by executing a Deed of
Adherence in the form attached hereto as Exhibit B to be subject to the terms of this Agreement to the same extent as if it were an original Investor hereunder; provided that this sentence shall terminate and be of no further force or effect
pursuant to Section 4.8. For purposes of this Agreement, “Person” or “person” shall mean any individual, corporation, partnership, limited partnership, proprietorship, association, limited
liability company, firm, trust, estate or other enterprise or entity. “Control” shall mean the power or authority, whether exercised or not, to direct the business, management and policies of a Person, directly or indirectly,
whether through the ownership of voting securities, by contract or otherwise; provided, that such power or authority shall conclusively be presumed to exist upon possession of beneficial ownership or power to direct the vote of more than fifty
percent (50%) of the votes entitled to be cast at a meeting of the members or shareholders of such Person or power to control the composition of a majority of the board of directors of such Person. The terms “Controlled” and
“Controlling” have meanings correlative to the foregoing. Notwithstanding anything to the contrary contained herein, no Investor shall be deemed to be an Affiliate (or Controlled Affiliate) of any Group Company and the Group
Companies shall not be deemed to be an Affiliate (or Controlled Affiliate) of any Investor. 

  
 39 

 12.7 Interpretation; Captions. This Agreement shall be construed according to its
fair language. The rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be employed in interpreting this Agreement. The captions to sections of this Agreement have been inserted for
identification and reference purposes only and shall not be used to construe or interpret this Agreement. Unless otherwise expressly provided herein, all references to Sections and Exhibits herein are to Sections and Exhibits of this Agreement. 

12.8 Counterparts. This Agreement may be executed in one or more counterparts and may be delivered by electronic or facsimile
transmission, all of which shall be considered one and the same agreement and each of which shall be deemed an original. 
 12.9
Adjustments for Share Splits, Etc. Wherever in this Agreement there is a reference to a specific number of shares of Series A Preferred Shares, Series B Preferred Shares, Ordinary Shares or Non-voting
Ordinary Shares of the Company, then, upon the occurrence of any subdivision, combination or share dividend of the Series A Preferred Shares, Series B Preferred Shares, Ordinary Shares or Non-voting Ordinary
Shares, the specific number of shares so referenced in this Agreement shall automatically be proportionally adjusted to reflect the effect on the outstanding shares of such class or series of shares by such subdivision, combination or share
dividend. 
 12.10 Aggregation of Shares. All Series A Preferred Shares, Series B Preferred Shares, Ordinary Shares or Non-voting Ordinary Shares held or acquired by Affiliated entities or Persons (as defined in Rule 144 under the Securities Act) shall be aggregated together for the purpose of determining the availability of any
rights under this Agreement. 
 12.11 Shareholders Agreement to Control. If and to the extent that there are inconsistencies between
the provisions of this Agreement and those of the Restated Articles, the terms of this Agreement shall prevail among the Parties to this Agreement other than the Company. The Parties other than the Company agree to take all actions necessary or
advisable, as promptly as practicable after the discovery of such inconsistency, to amend the Restated Articles so as to eliminate such inconsistency. 

12.12 Dispute Resolution. 

(a) Negotiation between Parties. The Parties agree to negotiate in good faith to resolve any dispute, controversy, difference or claim
arising out of or relating to this Agreement, including the existence, validity, interpretation, performance, breach or termination thereof between them regarding this Agreement. If the negotiations do not resolve the dispute to the reasonable
satisfaction of all Parties in dispute within thirty (30) days after one Party delivers notice of dispute to the others, Section 12.12(b) shall apply. 

(b) Arbitration. In the event the Parties in dispute are unable to settle a dispute between them regarding this Agreement in accordance
with subsection (i) above, such dispute shall be referred to and finally resolved by arbitration at the Hong Kong International Arbitration Centre (the “HKIAC”) for arbitration in Hong Kong. The arbitration shall be conducted
in accordance with the HKIAC Administered Arbitration Rules in force at the time 

  
 40 

 
of the initiation of the arbitration, which rules are deemed to be incorporated by reference into this subsection (ii). There shall be three (3) arbitrators. The complainant(s) and
respondent(s) to such dispute shall each nominate one (1) arbitrator with the third arbitrator jointly nominated by the disputing parties within thirty (30) days after the initiation of the arbitration. Each of the arbitrators so nominated
shall be qualified to practice the laws of Hong Kong. In the event that the disputing parties cannot jointly agree on the third arbitrator within such thirty (30) day period, the HKIAC shall appoint such arbitrator. The arbitral proceedings
shall be conducted in English. The award of the arbitral tribunal shall be final and binding upon the parties thereto. 
 12.13 Further
Actions. Each Shareholder agrees that it shall use its best effort to enhance and increase the value and principal business of the Group Companies. Further, to assist the Company to pursue a Qualified Initial Public Offering, each Shareholder
agrees to cooperate with the Company proactively and in good faith, including answering requests within reasonable time. 
 12.14
Waiver. The Company acknowledges that the Investors will likely have, from time to time, information that may be of interest to the Company or its Subsidiaries (“Information”) regarding a wide variety of matters including
(i) the technologies, plans and services, and plans and strategies relating thereto of such Investor, (ii) current and future investments such Investor has made, may make, may consider or may become aware of with respect to other companies
and other technologies, products and services, including technologies, products and services that may be competitive with those of the Company or any of its Subsidiaries, and (iii) developments with respect to the technologies, products and
services, and plans and strategies relating thereto, of other companies, including companies that may be competitive with the Company or any of its Subsidiaries. The Company recognizes that a portion of such Information may be of interest to the
Company or any of its Subsidiaries. Such Information may or may not be known by the Investors or the Investor Directors. The Company, as a material part of the consideration for this Agreement, agrees that the Investors or the Investor Directors
shall not have any duty to disclose any Information to the Company or any of its Subsidiaries, or permit the Company or any of its Subsidiaries to participate in any projects or investments based on any such Information, or otherwise to take
advantage of any opportunity that may be of interest to the Company or any of its Subsidiaries if it were aware of such Information, and hereby waives, to the extent permitted by law, any claim based on the corporate opportunity doctrine or
otherwise that could limit the Investors’ ability to pursue opportunities based on such Information or that would require the Investors, the Investor Directors or their representative(s), to disclose any such Information to the Company or any
of its Subsidiaries or offer any opportunity relating thereto to the Company or any of its Subsidiaries. 
 12.15 Additional
Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional Series B Preferred Shares after the date hereof pursuant to the Share Purchase Agreement, as such agreement may be amended from time to
time in accordance with its terms, any purchaser of such Series B Preferred Shares may become a Party to this Agreement by executing and delivering to the Company an additional counterpart signature page to this Agreement and thereafter shall be
deemed a “Series B Investor” for all purposes hereunder. 
 — REMAINDER OF THIS PAGE LEFT INTENTIONALLY BLANK —

  
 41 

 IN WITNESS WHEREOF, the Parties have caused their respective duly authorized representatives
to execute this Agreement as of the date and year first above written. 
  

			
	COMPANY:
	
	VISEN Pharmaceuticals
		
	By:	 	 /s/ [***]

	Name:	 	[***]
	Title:	 	Director

  

  
 SIGNATURE PAGE OF
SHAREHOLDERS AGREEMENT 

 IN WITNESS WHEREOF, the Parties have caused their respective duly authorized representatives
to execute this Agreement as of the date and year first above written. 
  

			
	INVESTORS:
	
	ASCENDIS PHARMA A/S
		
	By:	 	 /s/ Michael Wolff Jensen, /s/ Jan Møller Mikkelsen

	Name:	 	Michael Wolff Jensen / Jan Møller Mikkelsen
	Title:	 	Chairman / CEO
	
	
	ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S
		
	By:	 	 /s/ Michael Wolff Jensen, /s/ Jan Møller Mikkelsen

	Name:	 	Michael Wolff Jensen / Jan Møller Mikkelsen
	Title:	 	Chairman / CEO
	
	
	ASCENDIS PHARMA BONE DISEASES A/S
		
	By:	 	 /s/ Michael Wolff Jensen, /s/ Jan Møller Mikkelsen

	Name:	 	Michael Wolff Jensen / Jan Møller Mikkelsen
	Title:	 	Chairman / CEO
	
	
	 ASCENDIS PHARMA GROWTH DISORDERS

A/S

		
	By:	 	 /s/ Michael Wolff Jensen, /s/ Jan Møller Mikkelsen

	Name:	 	Michael Wolff Jensen / Jan Møller Mikkelsen
	Title:	 	Chairman / CEO
	

 SIGNATURE PAGE OF SHAREHOLDERS AGREEMENT 

 IN WITNESS WHEREOF, the Parties have caused their respective duly authorized representatives
to execute this Agreement as of the date and year first above written. 
  

			
	INVESTORS:
	
	VIVO PLENILUNE IX LIMITED
		
	By:	 	 /s/ [***]

	Name:	 	[***]
	Title:	 	Director

 SIGNATURE PAGE OF SHAREHOLDERS AGREEMENT 

 IN WITNESS WHEREOF, the Parties have caused their respective duly authorized representatives
to execute this Agreement as of the date and year first above written. 
  

			
	INVESTORS:
	
	Sofinnova Venture Partners IX, L.P.
	By: Sofinnova Management IX, L.L.C.
	Its: General Partner
		
	By:	 	 /s/ [***]

	Name:	 	[***]
	Title:	 	Managing Member

 SIGNATURE PAGE OF SHAREHOLDERS AGREEMENT 

 IN WITNESS WHEREOF, the Parties have caused their respective duly authorized representatives
to execute this Agreement as of the date and year first above written. 
  

			
	INVESTORS:
	
	SCC GROWTH VI HOLDCO F, LTD.
		
	By:	 	 /s/ [***]

	Name:	 	[***]
	Title:	 	Authorized Signatory

 SIGNATURE PAGE OF SHAREHOLDERS AGREEMENT 

 IN WITNESS WHEREOF, the Parties have caused their respective duly authorized representatives
to execute this Agreement as of the date and year first above written. 
  

			
	INVESTORS:
	
	SHERPA HEALTHCARE FUND I, L.P.
		
	By:	 	 /s/ [***]

	Name:	 	[***]
	Title:	 	Authorized Signatory
	
	SHERPA HEALTHCARE CO-INVESTMENT FUND, L.P.
		
	By:	 	 /s/ [***]

	Name:	 	[***]
	Title:	 	Authorized Signatory

 SIGNATURE PAGE OF SHAREHOLDERS AGREEMENT 

 IN WITNESS WHEREOF, the Parties have caused their respective duly authorized representatives
to execute this Agreement as of the date and year first above written. 
  

					
	INVESTORS:
	
	WORLDWIDE HEALTHCARE TRUST PLC
		 	By: OrbiMed Capital LLC, solely in its
		 	capacity as Portfolio Manager
			
		 	By:	 	 /s/ [***]

		 		 	Name: [***]
		 		 	Title: Authorized Signatory
	
	ORBIMED GENESIS MASTER FUND, L.P.
		
		 	 By: OrbiMed Genesis GP LLC,

		 	 its General Partner

		
		 	 By: OrbiMed Advisors LLC,

		 	 its Managing Member

			
		 	By:	 	 /s/ [***]

		 		 	Name: [***]
		 		 	Title: Authorized Signatory

  

							
	ORBIMED NEW HORIZONS MASTER FUND, L.P.
		 	By: OrbiMed New Horizons GP LLC, its General Partner
		 	        By: OrbiMed Advisors LLC, its Managing Member
				
		 		 	By:	 	 /s/ [***]

		 		 		 	Name: [***]
		 		 		 	Title: Authorized Signatory

 SIGNATURE PAGE OF SHAREHOLDERS AGREEMENT 

 IN WITNESS WHEREOF, the Parties have caused their respective duly authorized representatives
to execute this Agreement as of the date and year first above written. 
  

					
	INVESTORS:
	
	CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP
		 	 By: Cormorant Global Healthcare GP, LLC

			
		 	By:	 	 /s/ [***]

		 	Name:	 	[***]
		 	Title:	 	Managing Member

  

					
	
	CORMORANT PRIVATE HEALTHCARE FUND III, LP
		 	 By: Cormorant Private Healthcare GP, LLC

			
		 	By:	 	 /s/ [***]

		 	Name:	 	[***]
		 	Title:	 	Managing Member

  

					
	
	CRMA SPV, L.P.
		 	 By: Cormorant Asset Management, LP

			
		 	By:	 	 /s/ [***]

		 	Name:	 	[***]
		 	Title:	 	Attorney-in-fact

 SIGNATURE PAGE OF SHAREHOLDERS AGREEMENT 

 IN WITNESS WHEREOF, the Parties have caused their respective duly authorized representatives
to execute this Agreement as of the date and year first above written. 
  

			
	INVESTORS:
	
	HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD.
		
	By:	 	 /s/ [***]

	Name:	 	[***]
	Title:	 	Managing Director

 SIGNATURE PAGE OF SHAREHOLDERS AGREEMENT 

 IN WITNESS WHEREOF, the Parties have caused their respective duly authorized representatives
to execute this Agreement as of the date and year first above written. 
  

			
	INVESTORS:
	
	LOGOS OPPORTUNITIES FUND II, L.P.
	By: Logos Opportunities GP, LLC
	Its General Partner
		
	By:	 	 /s/ [***]

	Name:	 	[***]
	Title:	 	Managing Member
	
	Address: 1 Letterman Drive
	                Building D, Suite D3-700
	                San Francisco, CA 94129
		
	By:	 	 /s/ [***]

	Name:	 	[***]
	Title:	 	Managing Partner
	
	Address: 1 Letterman Drive
		 	    Building D, Suite D3-700
		 	    San Francisco, CA 94129

 SIGNATURE PAGE OF SHAREHOLDERS AGREEMENT 

 IN WITNESS WHEREOF, the Parties have caused their respective duly authorized representatives
to execute this Agreement as of the date and year first above written. 
  

			
	INVESTORS:
	
	COSMIC CLOVER LIMITED
		
	By:	 	 /s/ [***]

	Name:	 	[***]
	Title:	 	Director

 SIGNATURE PAGE OF SHAREHOLDERS AGREEMENT 

 IN WITNESS WHEREOF, the Parties have caused their respective duly authorized representatives
to execute this Agreement as of the date and year first above written. 
  

			
	INVESTORS:
	
	CRF INVESTMENT HOLDINGS COMPANY LIMITED
		
	By:	 	 /s/ [***]

	Name:	 	[***]
	Title:	 	Director

 SIGNATURE PAGE OF SHAREHOLDERS AGREEMENT 

 

 EXHIBIT A 

PARTIES 
 Part I Series A Investors

  

			
	 Name of Series A Investors
	  	Number of Series A
Preferred Shares
	 Ascendis Pharma Endocrinology Division A/S
	  	[***]
	 Ascendis Pharma Bone Diseases A/S
	  	[***]
	 Ascendis Pharma Growth Disorders A/S (together with Ascendis Pharma Endocrinology Division A/S and
Ascendis Pharma Bone Diseases A/S, “Ascendis”)
	  	[***]
	 Vivo Plenilune IX Limited (“Vivo Capital”)
	  	[***]
	 Sofinnova Venture Partners IX, L.P. (“Sofinnova”)
	  	[***]
	 Total
	  	[***]

  
 EXHIBIT A 

 Part II Series B Investors 

 

			
	 Name of Series B Investors
	  	Number of Series B
Preferred Shares
	 SCC Growth VI Holdco F, Ltd. (“Sequoia”)
	  	[***]
	 Sherpa Healthcare Fund I, L.P. (together with Sherpa Healthcare
Co-Investment Fund, L.P., collectively, “Sherpa”)
	  	[***]
	 Sherpa Healthcare Co-Investment Fund, L.P.
	  	[***]
	 Worldwide Healthcare Trust PLC (together with OrbiMed Genesis Master Fund, L.P., OrbiMed New
Horizons Master Fund, L.P., collectively, “OrbiMed”)
	  	[***]
	 OrbiMed Genesis Master Fund, L.P.
	  	[***]
	 OrbiMed New Horizons Master Fund, L.P.
	  	[***]
	 Cormorant Private Healthcare Fund III, LP (together with Cormorant Global Healthcare Master Fund,
LP, CRMA SPV, L.P., collectively, “Cormorant”)
	  	[***]
	 Cormorant Global Healthcare Master Fund, LP
	  	[***]
	 CRMA SPV, L.P.
	  	[***]
	 HBM Healthcare Investments (Cayman) Ltd. (“HBM”)
	  	[***]
	 Logos Opportunities Fund II, L.P. (“Logos”)
	  	[***]
	 Cosmic Clover Limited (“Pivotal”)
	  	[***]
	 CRF Investment Holdings Company Limited (“China Reform Overseas”)
	  	[***]
	 Vivo Capital
	  	[***]
	 Ascendis Pharma Endocrinology Division A/S
	  	[***]
	 Ascendis Pharma Bone Diseases A/S
	  	[***]
	 Ascendis Pharma Growth Disorders A/S
	  	[***]
	 Sofinnova
	  	[***]
	 TOTAL
	  	[***]

  
 EXHIBIT A 

 Part III Notice Address 

For the purpose of the notice provisions contained in this Agreement, the following are the initial addresses of each Party: 

If to the Company: 
 Address: Room 2501 1788 Square
No 1788 West Nanjing Road, Shanghai P.R.China 
 Attention: [***] 

E-mail address: [***] 

With a copy to: 
 Vivo Capital 

Address: 505 Hamilton Avenue, Suite 207, Palo Alto, CA 94301 

Tel: (650) 688-0818 

Attention: [***] 
 E-mail
address: [***] 
 and 
 Ascendis 

Address: Tuborg Boulevard 12 

                2900 Hellerup 

                Denmark 

Tel: +45 70 22 22 44 
 Attention: [***] 

E-mail address: [***] 

If to the Investors: 
 If to Ascendis 

Tuborg Boulevard 12 
 2900 Hellerup 

Denmark 
 Attention: [***] 

E-mail address: [***] 

If to Vivo Capital 
 505 Hamilton Avenue, Suite 207, Palo
Alto, CA 94301 
 Tel: (650) 688-0818 

Attention: [***] 
 E-mail
address: [***] 

  
 EXHIBIT A 

 If to Sofinnova 

3000 Sand Hill Road, Bldg. 4, Suite 250 
 Menlo Park, CA 94025

 Attention: [***] 

E-mail address: [***] 

If to Sequoia 
 Address: Maples Corporate Services Limited
PO Box 309 Ugland House Grand 
                 Cayman, KY1-1104, Cayman Islands 

                c/o Suite 3613, Two Pacific Place, 88 Queensway, Hong Kong 

Tel: (852) 2501 8989 
 Attention: [***] 

E-mail address: [***] 

If to Sherpa 
 Address: Huibin Plaza, No.8 East Beichen
Road, Room-A901, Chaoyang District, Beijing, 
                 China 

Attention: [***] 
 E-mail
address: [***] 
 If to OrbiMed 
 Address: 601 Lexington
Avenue, 54th Floor, New York, NY 10022 
 Tel: (212) 739-6400

 Attention: General Counsel 

E-mail address: [***] 

If to Cormorant 
 Address: 200 Clarendon Street 52nd Floor

                 Boston, MA 02116 

Tel: 857 702 0386 
 Fax: 617 507 5905 

Attention: [***] 
 E-mail
address: [***] 
 If to HBM 
 Address: Governors Square,
Suite #4-212-2 

                23 Lime Tree Bay Avenue 

                PO Box 30852 

                Grand Cayman, KY1-1204,
Cayman Islands 
 Tel: ++1.345.946.8002 
 Attention: [***] 

E-mail address: [***] 

  
 EXHIBIT A 

 If to Logos 

Address: Logos Capital 

                1 Letterman Dr., Ste
D3-700 
                 San
Francisco, CA 94129 
 Attention: [***] 
 E-mail address: [***] 
 If to Pivotal 

Address: c/o 23/F Nan Fung Tower, 88 Connaught Road C, Central, Hong Kong 

Tel: +852 3108 3633 
 Fax: +852 3162 5688 

Attention: [***] 
 If to China Reform Overseas 

Address: Suite 4704, Central Plaza, 18 Harbour Road, Wanchai, Hong Kong 

Attention: [***] 
 E-mail
address: [***] 

  
 EXHIBIT A 

 EXHIBIT B 

FORM OF DEED OF ADHERENCE 
 To: VISEN
Pharmaceuticals 
 Parties to the Shareholders Agreement (as defined below) 

 

			
	From:	 	                                      
          
		
	Date:	 	                                      
          

 Dear Sirs, 

Deed of Adherence 

The undersigned hereby agree and covenant with each of you pursuant to this Deed of Adherence that the undersigned will abide by all the
provisions of the Shareholders Agreement entered into by and among the Company and each of the parties named therein, dated as of January 8, 2021, as amended from time to time (the “Shareholders Agreement”), as the Investors
under the terms of the Shareholders Agreement and a party to the Shareholders Agreement. 
  

			
	[_________________]
	
	SIGNED, SEALED and DELIVERED
		
	By:	 	
                     
        

	Name:	 	
	Title:	 	

 Address 

  
 51EX-4.18

 Exhibit 4.18 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such
excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
 VISEN Pharmaceuticals 
 P.O.
Box 472 
 2nd Floor, Harbour Place 
 103 South Church Street

 George Town, Grand Cayman KY1-1106 

Cayman Islands 
 Attention: [***] 

4 January, 2021 
 Amendment to the
Exclusive Licence Agreement between Ascendis Pharma Growth Disorders A/S and Visen Pharmaceuticals dated 7 November 2018 (the “Agreement”) 

Dear Sirs or Madams 
 Further to the Parties’ recent
discussions regarding the Agreement, and in consideration of the Series B financing and the promises and mutual covenants set forth in this letter (including the appendix to this letter), we now wish to amend the Agreement as set out in the appendix
to this letter. 
 These amendments shall take effect on and from the closing of the Series B financing. For the avoidance of doubt, all capitalised terms
shall have the meaning given to them in the Agreement unless separately defined in this letter.  
 We confirm that all other terms and conditions of
the Agreement remain unchanged and continue in full force and effect. 
 Please confirm your acceptance to these terms by countersigning this letter and the
enclosed copy of this letter and returning the copy to us at [***] marked for the attention of [***], as soon as possible and, in any event, by 4 January 2021. 

Yours faithfully 
  

					
	 /s/ Jan Møller Mikkelsen
	  	            	  	 /s/ Michael Wolff Jensen

	Jan Møller Mikkelsen, CEO	  		  	Michael Wolff Jensen, Chairman of the board of directors
			
	for and on behalf of Ascendis Pharma Growth Disorders A/S	  		  	

 Accepted and agreed: 
 /s/
[***]                                 

[***], Director for and on behalf of Visen Pharmaceuticals 
  

					
	Tuborg Boulevard 12  |   DK-2900 Hellerup  |  Tel +45 70 22 22 44  |  www.ascendispharma.com  |  cvr DK-29918791	  	 	
 1
	 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).
Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
  

 Appendix : Amendments 

 

	1.	 A new definition of Ascendis Alliance Manager shall be inserted and read as follows: 

“Ascendis Alliance Manager” means an FTE individual designated by Ascendis to ensure communication and alignment
between Ascendis and Licensee regarding activities carried out by either Party under this Agreement. The annual FTE rate of such Ascendis Alliance Manager shall be EUR [***].” 

 

	2.	 A new definition of Commercialisation Plan shall be inserted and read as follows: 

““Commercialisation Plan” has the meaning ascribed to it in Clause 4.8.” 

 

	3.	 A new definition of Good Pharmacovigilance Practice shall be inserted and read as follows:

 ““Good Pharmacovigilance Practice” means the applicable principles and guidelines for
good pharmacovigilance practice for drugs and medicinal products, as such principles and guidelines are amended, implemented and supplemented from time-to-time,
including without limitation those set out in the European Medicines Agency’s GVP modules I to XVI.” 
  

	4.	 A new definition of Technology Transfer Plan shall be inserted and read as follows: 

““Technology Transfer Plan” means: the plan mutually agreed and signed by the Parties for the transfer of
Ascendis Technical Information from Ascendis to Licensee to the extent necessary to permit Licensee to Manufacture Licensed Products within the Territory. Such Technology Transfer Plan shall include (without limitation): (i) [***].” All
reasonable costs in accordance with the budget set forth in the technology Transfer Plan shall be covered by Licensee (including [***], all as agreed by Licensee in the Technology Transfer Plan). 

 

	5.	 Clause 4.3 of the Agreement shall be deleted and replaced with the following: 

“The Licensee shall be solely responsible for any clinical trial activities carried out as part of its development and
commercialisation activities in the Territory. For such clinical trials, Licensee shall coordinate with Ascendis so that clinical endpoints, inclusion and exclusion criteria for the clinical trial are aligned with clinical trials conducted by
Ascendis outside the Territory in similar indications, unless specific deviations are requested by the Regular Authority in the Territory, in which case the Parties shall in good faith discuss to propose an acceptable endpoint, inclusion or
exclusion criteria with the Regulatory Authorities. However, if clinical trials are performed in the Territory in respect of the Licensed Product as part of a single global study to support Regulatory Approval in at least [***] in respect of the
Licensed Product (“Multi-territory Study/ies”), then the performance of such Multi-territory Studies in the Territory shall be subject to the Parties’ mutual agreement and the Parties’ agreement in advance,
in writing, as to their respective obligations in respect of any such Multi-territory Study, including (without limitation) the Parties’ respective responsibilities for: [***]. If the Parties are unable to agree such matters in advance, the
Licensee shall not participate in such Multi-territory Study.” 

  

			
	Tuborg Boulevard 12  |   DK-2900 Hellerup  |  Tel +45 70 22 22 44  |  www.ascendispharma.com  |  cvr DK-29918791	  	2

 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).
Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
  

	6.	 Clause 4.4 of the Agreement shall be amended to read as follows: 

“The Licensee shall use Diligent Efforts to develop and commercialise Licensed Product in the Field in the Territory. The Licensee
shall ensure that such development and commercialisation of the Licensed Product are consistent with the Research and Technical Development Plan and Commercialisation Plan.” 

 

	7.	 Clause 4.5 of the Agreement shall be amended to read as follows: 

“Each Party shall conduct all development of Licensed Product in compliance with Applicable Laws, which shall include Good Laboratory
Practice, Good Clinical Practice, Good Pharmacovigilance Practice and Good Manufacturing Practice, in each case, where applicable. Neither Party shall use any person that has been debarred, disqualified or banned from practising medicine to perform
activities under this Agreement, and each Party shall immediately notify the other Party in writing if any person performing activities under this Agreement is disqualified, debarred or banned from practising medicine.” 

 

	8.	 A new Clause 4.7 shall be inserted into the Agreement and read as follows: 

“4.7 Joint Commercialisation Committee.  

(A) Formation of the JCC. At least [***] prior to the first commercial sale of the Licensed Product in the Field in the Territory, the
Parties will form a Joint Commercialisation Committee comprised of [***] (the “JCC”). 
 (B) One representative of
the Licensee at the JCC will be selected to act as the chairperson of the JCC. The JCC will meet at least [***] ([***]) times per year and such meetings may be conducted by videoconference, teleconference or in person, as agreed by the Parties. The
JCC will agree upon the time and location of the meetings. The chairperson, or his or her designee, will circulate an agenda for each meeting approximately [***] before the date scheduled for the meeting, and will include all matters requested to be
included on such agenda by either Party. The chairperson, or his or her designee, will take complete and accurate minutes of all discussions occurring at the JCC meetings and all matters decided upon at the meetings except that matters reflecting
legal advice of counsel will not be included in such minutes. A copy of the draft minutes of each meeting will be provided to each Party by the chairperson, or his or her designee, after each meeting, and such minutes will be reviewed by the JCC
members, any needed changes discussed and final minutes agreed to and provided to each Party within [***] after each meeting unless otherwise agreed. A reasonable number of additional representatives of a Party may attend meetings of the JCC in a non-voting capacity. Each Party is responsible for its personnel and travel costs and expenses associated with attending meetings. 

  

			
	Tuborg Boulevard 12  |   DK-2900 Hellerup  |  Tel +45 70 22 22 44  |  www.ascendispharma.com  |  cvr DK-29918791	  	3

 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).
Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
  

 (C) JCC functions and powers. The responsibilities of the JCC will be as follows: 

(1) encouraging and facilitating communication between the Parties with respect to the commercialisation of Licensed Product(s)) in the
Field in the Territory; 
 (2) [***] the first Commercialisation Plan pursuant to Clause 4.8; 

(3) [***] the Commercialisation Plan [***] and [***]; 

(4) exchanging information on the progress of the commercialisation of the Licensed Product in the Field in the Territory; and 

(5) carrying out the other duties and responsibilities described for it in this Agreement. 

(D) JCC Decision Making. All decisions of the JCC will be made by unanimous vote, with each of Ascendis and Licensee having one vote and the
decisions will be recorded in the JCC minutes. If after reasonable discussion and consideration of each of the Parties’ views on a particular matter before the JCC, the JCC is unable to reach a decision by unanimous vote on that matter, the
following shall apply: 
 (a) the disputed matter shall be [***]; 

(b) irrespective of above Clause 4.7 (D) (a), [***]. The JCC shall not have any authority other than that expressly set forth above and,
specifically, shall have no authority: [***] 
 (E) Duration of the JCC. The JCC shall continue in full force and effect unless and
until this Agreement expires or is terminated in accordance with Clause 18.” 
  

	9.	 A new Clause 4.8 shall be inserted into the Agreement and read as follows: 

“4.8 Promptly following the establishment of the JCC, Licensee shall present to the JCC a plan setting out the commercial strategy for
the commercialisation of the Licensed Products in the Field in the Territory including (without limitation) relating to branding, promotional materials, positioning in the market and medical affairs activities (including detailing),
which with respect to content may not be inconsistent with the commercial strategy for the commercialisation of the Licensed Products in the Field outside the Territory) (the “Commercialisation Plan”).
Such plan shall be [***] the JCC [***] thereafter no later than [***] and the JCC [***].”  
  

	10.	 A new Clause 4.9 shall be inserted into the Agreement and read as follows: 

“Promotional materials: 
  

	 	(A)	 Promotional materials including pre-marketing medical information
material for the Licensed Products for use in the Territory shall be developed by the Licensee, comply with Applicable Laws and Regulatory Approvals (including approved label of the Licensed Product), and be scientifically accurate and consistent
with data generated for the Licensed Product inside and outside the Territory. Copies of such materials shall be archived by the Parties to the extent required by Applicable Laws 

  

			
	Tuborg Boulevard 12  |   DK-2900 Hellerup  |  Tel +45 70 22 22 44  |  www.ascendispharma.com  |  cvr DK-29918791	  	4

 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).
Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
  

	 	(B)	 The Licensee shall submit English translations of samples of all such promotional materials to Ascendis, in
advance of being used, for Ascendis’ review and comment. Ascendis shall provide any comment to Licensee in writing within [***] of receipt of such samples and Licensee shall consider such comments in good faith and incorporate such comments.
 

  

	 	(C)	 The Licensee shall incorporate comments provided by Ascendis pursuant to above subsection 4.9 (B) to the
extent they correct any scientific inaccuracy and / or correct any statements that are in contrast to any accurate statement regarding the Licensed Product used outside the Territory..” 

 

	11.	 Clause 5.2(B) of the Agreement shall be amended to read as follows: 

“conduct all relevant packaging and distribution in accordance with Applicable Laws, which shall include Good Manufacturing Practice
and Good Distribution Practice, in each case, to the extent applicable. In addition, Ascendis shall provide Licensee with written instructions in advance as to the best practice for handling and storing the Licensed Product and Licensee shall follow
such instructions.” 
  

	12.	 A new Clause 5.3 shall be inserted into the Agreement and read as follows: 

“5.3 Technology Transfer  

5.3(A) If Licensee wishes to Manufacture Licensed Product in the Territory (including the TransCon [***], TransCon [***] or any other
component which is proprietary to Ascendis or its CMO’s and necessary for the manufacture of the Licensed Product, but excluding the TransCon [***]) by itself or (subject to prior approval in writing by Ascendis, not to be unreasonably
withheld, delayed or conditioned) via its subcontractors, it shall notify Ascendis of the same in writing, and the Parties shall cooperate in good faith to agree on a Technology Transfer Plan to implement the transfer of such Ascendis Technical
Information (after relevant approval from affected CMO’s) to the extent necessary to permit Licensee to Manufacture the Licensed Products in the Territory. The Licensee shall be responsible for the following: 

(a) the Manufacture of the Licensed Products by Licensee shall comply with standards required by the FDA and the European Medicines Agency,
any International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (“ICH”) guidance, and Good Manufacturing Practice; and audited by Ascendis; and 

(b) the Manufacturing process used following any technology transfer pursuant to this Clause 5.3 shall be, unless otherwise agreed to by
Ascendis, identical or comparable (or modified solely to the extent necessary to meet local regulatory requirements) to the Manufacturing process used outside the Territory immediately prior to such technology transfer; and 

(c) the Licensed Product manufactured by Licensee following a technology transfer shall be comparable to Licensed Product manufactured by
Ascendis as determined in accordance with relevant guidelines issued by FDA and EMA. Licensee shall document in writing such comparability to Ascendis prior to any clinical or commercial use of Licensed Product by Licensee. 

  

			
	Tuborg Boulevard 12  |   DK-2900 Hellerup  |  Tel +45 70 22 22 44  |  www.ascendispharma.com  |  cvr DK-29918791	  	5

 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).
Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
  

 Licensee acknowledges and agrees that any such technology transfer may be subject to the
consent of Ascendis’ contract manufacturer(s) and any conditions and/or fees imposed by such contract manufacturer(s) in respect of the same. Ascendis shall seek the consent of such contract manufacturer(s) acting in good faith, provided that
if such consent is not obtained, no transfer shall occur in respect of the activities performed by such contract manufacturer(s). 

Promptly following the Parties agreeing to the content of the Technology Transfer Plan, the Parties shall perform the transfer from Ascendis
or its contract manufacturer to Licensee (or its subcontractor if approved in writing by Ascendis) of the Ascendis Technical Information necessary to permit Licensee to Manufacture the Licensed Products in the Territory, in accordance with the
relevant Technology Transfer Plan. Each Party shall use reasonable efforts to complete the tasks assigned to such Party under the Technology Transfer Plan in a timely manner and in accordance with the Technology Transfer Plan. Each Party shall
designate qualified personnel having the necessary skill, expertise, and experience to facilitate such technology transfer and who shall be responsible for coordinating the technology transfer activities under the Technology Transfer Plan. Each
Party shall cooperate with the other Party in such other Party’s conduct of technology transfer activities under the Technology Transfer Plan. For the avoidance of doubt, such technology transfer shall not result in any change in the ownership
or Control of any of the Ascendis Patents, Ascendis Technical Information, Ascendis Platform Technology, Ascendis Program IP or Joint Program IP, and all Technical Information so transferred to the Licensee for the Manufacture of Licensed Products
constitutes Ascendis’ Confidential Information. As between the Parties, Licensee shall be solely responsibility for obtaining and maintaining and shall own all Regulatory Approvals for its (or its subcontractor’s) manufacture of Licensed
Product from Regulatory Authorities in each of the jurisdictions in the Territory in the Field, and associated costs. 
 5.3(C)
Licensee shall pay Ascendis’ FTE Costs and travel costs incurred in the performance of the Technology Transfer Plan and all costs of any materials transferred to Licensee, in each case in accordance with the Technology Transfer Plan, subject to
receipt of an invoice from Ascendis for such amounts. Licensee shall further pay any reasonable contract manufacturer’s fees in connection with such technology transfer that Licensee agreed to pay as part of the Technology Transfer Plan. All
other costs and expenses incurred by either Party in connection with the performance of the Technology Transfer Plan shall be borne by the incurring Party. 

5.3(D) If, at any time after such technology transfer, the Manufacture of the Licensed Product by Licensee (or its subcontractors) fails to
comply with Applicable Laws or the requirements set out in Clause 5.3(A)(a) – (c), then the Parties shall promptly confer and discuss an appropriate plan to remedy such failure for the future Manufacture of Licensed Product by Licensee (or its
subcontractors).” 

  

			
	Tuborg Boulevard 12  |   DK-2900 Hellerup  |  Tel +45 70 22 22 44  |  www.ascendispharma.com  |  cvr DK-29918791	  	6

 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).
Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
  

	13.	 Clause 6.4 shall be amended to read as follows: 

“6.4 The Licensee undertakes to comply, and to procure that its Sub-Licensees and contractors
comply, with all requirements of Regulatory Authorities, Applicable Laws, which shall include Good Laboratory Practice, Good Manufacturing Practice, Good Distribution Practice and Good Pharmacovigilance Practice, in each case to the extent
applicable.” 
  

	14.	 Clause 6.5 shall be amended to read as follows: 

“Ascendis shall provide assistance and information as reasonably requested by the Licensee in support of such regulatory activities,
[***]. In addition to [***], Licensee shall bear the cost for any additional services conducted by the Ascendis Alliance Manager for the Licensee that is not already reimbursed by Licensee otherwise (e.g., reimbursed as part of the research,
development or regulatory assistance), [***], provided that the Parties shall mutually agree upon the scope and time to be spent on such additional services prior to the Ascendis Alliance Manager conducting any such services.” 

 

	15.	 Clause 8 shall be amended to read as follows: 

“Each Party will maintain complete and accurate books, records and accounts in connection with its performance of this Agreement
(including, without limitation, those used for the determination of any payment obligations under this Agreement). Such books, records and accounts will be retained by such Party until [***] ([***]) years after the end of the period to which such
books, records and accounts pertain. The Licensee shall retain such books, records and accounts for an additional [***] ([***]) years if reasonably available and required by the applicable tax authority. During the term of the Agreement and for a
period of [***] thereafter, each Party, its Affiliates and/or their nominee may review and inspect such books, records, and accounts for the sole purpose of determining such other Party’s compliance with this Agreement (including, without
limitation, compliance with Clauses 4, 5, 6, 7, 9 and 10). Such review and inspection shall not take place more than [***] and shall be subject to the inspecting Party giving the other Party reasonable advance notice of such review and inspection
and such review and inspection shall take place during normal business hours at a mutually agreed upon time (such agreement not to be unreasonably withheld, delayed or conditioned). The inspecting Party shall bear its own expenses, and the other
Party shall reasonably cooperate with the inspecting Party, its Affiliates and/or nominee, in connection with any inspection. To the extent that any significant deficiencies are identified as the result of such inspection, the inspected Party shall
take all reasonable corrective measures to remedy any such significant deficiencies. For clarity, any review or inspection pursuant to this Clause 8 shall be subject to the terms of Clause 10 and this Clause 8 shall survive the termination or expiry
of this Agreement for [***].” 

  

			
	Tuborg Boulevard 12  |   DK-2900 Hellerup  |  Tel +45 70 22 22 44  |  www.ascendispharma.com  |  cvr DK-29918791	  	7

 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).
Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
  

	16.	 A new Clause 9.3 shall be inserted into the Agreement and read as follows: 

“9.3 Each Party shall perform all pharmacovigilance in respect of the Licensed Product in compliance with Applicable Laws, which shall
include Good Pharmacovigilance Practice to the extent applicable. As soon as practicable after the date of this letter, the Parties shall negotiate in good faith and enter into a pharmacovigilance agreement governing the pharmacovigilance activities
of the Parties with respect to the Licensed Product.” 
  

	17.	 This letter, once executed by both Parties, shall be deemed incorporated into the Agreement and all
terms and conditions of the Agreement (including without limitation Clauses 1, 15, 18 (where Clauses 4.9 (A) and (C), 5.3(D), 6.4 and Clause 8 shall be added to the list of material obligations under Clause 18.2(b)), 19, 20 and 21), unless expressly
modified in this letter, shall apply. 

  

			
	Tuborg Boulevard 12  |   DK-2900 Hellerup  |  Tel +45 70 22 22 44  |  www.ascendispharma.com  |  cvr DK-29918791	  	8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}]]